HRP20030163A2 - Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases - Google Patents
Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases Download PDFInfo
- Publication number
- HRP20030163A2 HRP20030163A2 HR20030163A HRP20030163A HRP20030163A2 HR P20030163 A2 HRP20030163 A2 HR P20030163A2 HR 20030163 A HR20030163 A HR 20030163A HR P20030163 A HRP20030163 A HR P20030163A HR P20030163 A2 HRP20030163 A2 HR P20030163A2
- Authority
- HR
- Croatia
- Prior art keywords
- cyano
- piperidin
- methyl
- cyclohexyl
- ylcarbamoyl
- Prior art date
Links
- 102000005927 Cysteine Proteases Human genes 0.000 title description 22
- 108010005843 Cysteine Proteases Proteins 0.000 title description 22
- 239000003112 inhibitor Substances 0.000 title description 20
- 150000002825 nitriles Chemical class 0.000 title description 16
- 230000002441 reversible effect Effects 0.000 title description 16
- -1 4-{[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]ethoxycarbonylamino-methyl}-piperazin-1-yl Chemical group 0.000 claims description 496
- 150000001875 compounds Chemical class 0.000 claims description 126
- 238000000034 method Methods 0.000 claims description 74
- PZHVJOASLUENNR-UHFFFAOYSA-N 4-amino-1-propylpiperidine-4-carbonitrile Chemical compound CCCN1CCC(N)(C#N)CC1 PZHVJOASLUENNR-UHFFFAOYSA-N 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 17
- 229940080818 propionamide Drugs 0.000 claims description 16
- KBZKISBFIGBTRZ-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-(2,6-dimethylmorpholin-4-yl)carbonimidoyl]carbamate Chemical compound C1C(C)OC(C)CN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 KBZKISBFIGBTRZ-UHFFFAOYSA-N 0.000 claims description 10
- TXSWHPXKIHOFFW-UHFFFAOYSA-N [n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamic acid Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=NC(O)=O)N1CCOCC1)CC1CCCCC1 TXSWHPXKIHOFFW-UHFFFAOYSA-N 0.000 claims description 9
- KWDFOVZJLGGFEJ-UHFFFAOYSA-N 2,2-dimethylpropyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC(C)(C)C)N1CCOCC1)CC1CCCCC1 KWDFOVZJLGGFEJ-UHFFFAOYSA-N 0.000 claims description 8
- UZXJWOJKLANKLW-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-3-cyclooctyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]propanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(N=C1C=2C=CC=CC=2OC(=O)N1)CC1CCCCCCC1 UZXJWOJKLANKLW-UHFFFAOYSA-N 0.000 claims description 8
- YKZKUZBOIVQPKH-UHFFFAOYSA-N 2-(2-methylpropoxy)ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OCCOCC(C)C)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 YKZKUZBOIVQPKH-UHFFFAOYSA-N 0.000 claims description 7
- ZZECMAPADXDGCI-UHFFFAOYSA-N 2-[(7-chloro-2-oxo-1,3-benzoxazin-4-yl)amino]-n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethylpentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C1C(C=CC(Cl)=C2)=C2OC(=O)N1 ZZECMAPADXDGCI-UHFFFAOYSA-N 0.000 claims description 7
- LJQBXYJOUSGFNQ-UHFFFAOYSA-N 2-methoxyethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OCCOC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 LJQBXYJOUSGFNQ-UHFFFAOYSA-N 0.000 claims description 7
- KSTYVHMXTVVGEQ-UHFFFAOYSA-N 2-propan-2-yloxyethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OCCOC(C)C)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 KSTYVHMXTVVGEQ-UHFFFAOYSA-N 0.000 claims description 7
- HRIAHQGTSYVRNE-UHFFFAOYSA-N 3,3,3-trifluoropropyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCCC(F)(F)F)N1CCOCC1)CC1CCCCC1 HRIAHQGTSYVRNE-UHFFFAOYSA-N 0.000 claims description 7
- ZQIPZPOBILDJOG-UHFFFAOYSA-N 3-methoxybutyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OCCC(C)OC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 ZQIPZPOBILDJOG-UHFFFAOYSA-N 0.000 claims description 7
- HGWWFNFNRZKTIM-UHFFFAOYSA-N cyclohexylmethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=NC(=O)OCC1CCCCC1)N1CCOCC1)CC1CCCCC1 HGWWFNFNRZKTIM-UHFFFAOYSA-N 0.000 claims description 7
- BZJDRVNKPJHZOK-UHFFFAOYSA-N ethyl n-[n-[1-[(1-benzyl-4-cyanopiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(CC=2C=CC=CC=2)CC1)C#N)CC1CCCCC1 BZJDRVNKPJHZOK-UHFFFAOYSA-N 0.000 claims description 7
- MYUDXAXYHFUKII-UHFFFAOYSA-N ethyl n-[n-[1-[(3-cyano-1-ethylpyrrolidin-3-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CN(CC)CC1)C#N)CC1CCCCC1 MYUDXAXYHFUKII-UHFFFAOYSA-N 0.000 claims description 7
- JUISAOVTXYFCRR-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-ethylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(CC)CC1)C#N)CC1CCCCC1 JUISAOVTXYFCRR-UHFFFAOYSA-N 0.000 claims description 7
- ASZOKEVTNWQRHX-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-3-cycloheptyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC)N1CCOCC1)CC1CCCCCC1 ASZOKEVTNWQRHX-UHFFFAOYSA-N 0.000 claims description 7
- HWSDONNUHGFBMR-UHFFFAOYSA-N ethyl n-[n-[1-[[4-cyano-1-(cyclohexylmethyl)piperidin-4-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(CC2CCCCC2)CC1)C#N)CC1CCCCC1 HWSDONNUHGFBMR-UHFFFAOYSA-N 0.000 claims description 7
- SVOLJUMFERLSGS-UHFFFAOYSA-N methyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 SVOLJUMFERLSGS-UHFFFAOYSA-N 0.000 claims description 7
- NVNTXQLHWCUJEO-UHFFFAOYSA-N n-(1-butyl-4-cyanopiperidin-4-yl)-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound C1CN(CCCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NC(=O)OC2=C1C=CC=C2 NVNTXQLHWCUJEO-UHFFFAOYSA-N 0.000 claims description 7
- IMGNPZFCQRLJOR-UHFFFAOYSA-N n-(4-cyano-1-ethylpiperidin-4-yl)-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound C1CN(CC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NC(=O)OC2=C1C=CC=C2 IMGNPZFCQRLJOR-UHFFFAOYSA-N 0.000 claims description 7
- JADQTIZWFMMUQF-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]propanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC=1C=2C=CC=CC=2OC(=O)N=1)CC1CCCCC1 JADQTIZWFMMUQF-UHFFFAOYSA-N 0.000 claims description 7
- NUISYAXZKITYMI-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-[(7,8-difluoro-2-oxo-1,3-benzoxazin-4-yl)amino]propanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC=1C=2C=CC(F)=C(F)C=2OC(=O)N=1)CC1CCCCC1 NUISYAXZKITYMI-UHFFFAOYSA-N 0.000 claims description 7
- OQWNZIKWJLVKLV-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-4-cyclohexyl-2-[(7-fluoro-2-oxo-1,3-benzoxazin-4-yl)amino]butanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C1C=2C=CC(F)=CC=2OC(=O)N1)CCC1CCCCC1 OQWNZIKWJLVKLV-UHFFFAOYSA-N 0.000 claims description 7
- QHJDVJWIBQLZSK-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-4-cyclohexyl-2-[(7-methoxy-2-oxo-1,3-benzoxazin-4-yl)amino]butanamide Chemical compound C=1C(OC)=CC=C2C=1OC(=O)NC2=NC(C(=O)NC1(CCN(C)CC1)C#N)CCC1CCCCC1 QHJDVJWIBQLZSK-UHFFFAOYSA-N 0.000 claims description 7
- MOKIXBLHBYPWQU-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-3-(4,4-dimethylcyclohexyl)-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]propanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(NC=1C=2C=CC=CC=2OC(=O)N=1)CC1CCC(C)(C)CC1 MOKIXBLHBYPWQU-UHFFFAOYSA-N 0.000 claims description 7
- UPMXGRIUMBAVEX-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethyl-2-[(1-methyl-2-oxoquinazolin-4-yl)amino]pentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NC(=O)N(C)C2=CC=CC=C12 UPMXGRIUMBAVEX-UHFFFAOYSA-N 0.000 claims description 7
- ORVYWDDKUPYYFO-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C1C(C=CC=C2)=C2OC(=O)N1 ORVYWDDKUPYYFO-UHFFFAOYSA-N 0.000 claims description 7
- FCXUUJAMSNIVKM-UHFFFAOYSA-N n-[4-cyano-1-(cyclohexylmethyl)piperidin-4-yl]-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound N=1C(=O)OC=2C=CC=CC=2C=1NC(CC(C)(C)C)C(=O)NC(CC1)(C#N)CCN1CC1CCCCC1 FCXUUJAMSNIVKM-UHFFFAOYSA-N 0.000 claims description 7
- VTSGBMMFCPIBBS-UHFFFAOYSA-N n-[4-cyano-1-[(4-fluorophenyl)methyl]piperidin-4-yl]-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound N=1C(=O)OC=2C=CC=CC=2C=1NC(CC(C)(C)C)C(=O)NC(CC1)(C#N)CCN1CC1=CC=C(F)C=C1 VTSGBMMFCPIBBS-UHFFFAOYSA-N 0.000 claims description 7
- IAWLBMBWKPOZPQ-UHFFFAOYSA-N n-[4-cyano-1-[(5-methylthiophen-2-yl)methyl]piperidin-4-yl]-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound S1C(C)=CC=C1CN1CCC(C#N)(NC(=O)C(CC(C)(C)C)NC=2C=3C=CC=CC=3OC(=O)N=2)CC1 IAWLBMBWKPOZPQ-UHFFFAOYSA-N 0.000 claims description 7
- TUEGPSRCECYDCB-UHFFFAOYSA-N oxolan-3-ylmethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=NC(=O)OCC1COCC1)N1CCOCC1)CC1CCCCC1 TUEGPSRCECYDCB-UHFFFAOYSA-N 0.000 claims description 7
- AXTPJGUZGRQXEW-UHFFFAOYSA-N (4-methoxycyclohexyl)methyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CC(OC)CCC1COC(=O)N=C(N1CCOCC1)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 AXTPJGUZGRQXEW-UHFFFAOYSA-N 0.000 claims description 6
- QBFHFPZRNKFWFP-UHFFFAOYSA-N 2-methylpropyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OCC(C)C)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 QBFHFPZRNKFWFP-UHFFFAOYSA-N 0.000 claims description 6
- DWQKYEQZHBUQQU-UHFFFAOYSA-N 2-methylpropyl n-[n-[1-[[4-cyano-1-[3-(2-methoxyethoxy)propyl]piperidin-4-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCCOCCOC)CCC1(C#N)NC(=O)C(NC(=NC(=O)OCC(C)C)N1CCOCC1)CC1CCCCC1 DWQKYEQZHBUQQU-UHFFFAOYSA-N 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- QMYAEYSZDOQAQU-UHFFFAOYSA-N C(#N)C1(CCN(CC1)C(C)C1=CC=CC=C1)NC(C(CC(C)(C)C)NC1=NC(OC2=C1C=CC=C2)=O)=O Chemical compound C(#N)C1(CCN(CC1)C(C)C1=CC=CC=C1)NC(C(CC(C)(C)C)NC1=NC(OC2=C1C=CC=C2)=O)=O QMYAEYSZDOQAQU-UHFFFAOYSA-N 0.000 claims description 6
- QMDIUDYRGAMUOZ-UHFFFAOYSA-N cyclobutyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=NC(=O)OC1CCC1)N1CCOCC1)CC1CCCCC1 QMDIUDYRGAMUOZ-UHFFFAOYSA-N 0.000 claims description 6
- DVQXDNHZFREEOJ-UHFFFAOYSA-N cyclobutylmethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC1CCC1)N1CCOCC1)CC1CCCCC1 DVQXDNHZFREEOJ-UHFFFAOYSA-N 0.000 claims description 6
- CTDYSNHNPCWMES-UHFFFAOYSA-N cyclohexyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=NC(=O)OC1CCCCC1)N1CCOCC1)CC1CCCCC1 CTDYSNHNPCWMES-UHFFFAOYSA-N 0.000 claims description 6
- AUAPCPRGOMWTLP-UHFFFAOYSA-N ethyl n-[c-(3-acetamidopyrrolidin-1-yl)-n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]carbonimidoyl]carbamate Chemical compound C1CC(NC(C)=O)CN1C(NC(=O)OCC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 AUAPCPRGOMWTLP-UHFFFAOYSA-N 0.000 claims description 6
- ZKNFOWFRKCRWJU-UHFFFAOYSA-N ethyl n-[c-(azepan-1-yl)-n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]carbonimidoyl]carbamate Chemical compound C1CCCCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 ZKNFOWFRKCRWJU-UHFFFAOYSA-N 0.000 claims description 6
- QMBNYJLSFJHOPM-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-(4-phenylpiperazin-1-yl)carbonimidoyl]carbamate Chemical compound C1CN(C=2C=CC=CC=2)CCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 QMBNYJLSFJHOPM-UHFFFAOYSA-N 0.000 claims description 6
- FVQSHEJIJRQVTJ-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-phenylcarbonimidoyl]carbamate Chemical compound C=1C=CC=CC=1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 FVQSHEJIJRQVTJ-UHFFFAOYSA-N 0.000 claims description 6
- HAZFOZMOXRLOLM-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propan-2-ylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(CC1)C(C)C)C#N)CC1CCCCC1 HAZFOZMOXRLOLM-UHFFFAOYSA-N 0.000 claims description 6
- MMXZMERDSYTTLW-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-c-phenylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC(=NC(=O)OCC)C1=CC=CC=C1 MMXZMERDSYTTLW-UHFFFAOYSA-N 0.000 claims description 6
- KWRVDDLYAQKIMY-UHFFFAOYSA-N hexyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OCCCCCC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 KWRVDDLYAQKIMY-UHFFFAOYSA-N 0.000 claims description 6
- ASAXBZDIRNRZPL-UHFFFAOYSA-N n-(1-benzyl-4-cyanopiperidin-4-yl)-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound N=1C(=O)OC=2C=CC=CC=2C=1NC(CC(C)(C)C)C(=O)NC(CC1)(C#N)CCN1CC1=CC=CC=C1 ASAXBZDIRNRZPL-UHFFFAOYSA-N 0.000 claims description 6
- CGDTZPXDMHRZBJ-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NC(=O)OC2=C1C=CC=C2 CGDTZPXDMHRZBJ-UHFFFAOYSA-N 0.000 claims description 6
- HAZCBXOAGZNLSM-UHFFFAOYSA-N n-(4-cyano-1-pentylpiperidin-4-yl)-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound C1CN(CCCCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NC(=O)OC2=C1C=CC=C2 HAZCBXOAGZNLSM-UHFFFAOYSA-N 0.000 claims description 6
- XLCAMYPAYUKOFJ-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethyl-2-[(2-oxo-1h-quinazolin-4-yl)amino]pentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C1C2=CC=CC=C2NC(=O)N1 XLCAMYPAYUKOFJ-UHFFFAOYSA-N 0.000 claims description 6
- LAEMLWCSDHZTCA-UHFFFAOYSA-N n-[4-cyano-1-(2,2-dimethylpropyl)piperidin-4-yl]-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound N=1C(=O)OC=2C=CC=CC=2C=1NC(CC(C)(C)C)C(=O)NC1(C#N)CCN(CC(C)(C)C)CC1 LAEMLWCSDHZTCA-UHFFFAOYSA-N 0.000 claims description 6
- KXBXTVFTYOQEQS-UHFFFAOYSA-N n-[4-cyano-1-(3,3,3-trifluoropropyl)piperidin-4-yl]-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound N=1C(=O)OC=2C=CC=CC=2C=1NC(CC(C)(C)C)C(=O)NC1(C#N)CCN(CCC(F)(F)F)CC1 KXBXTVFTYOQEQS-UHFFFAOYSA-N 0.000 claims description 6
- NPSARFACXNWHCR-UHFFFAOYSA-N oxolan-2-ylmethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=NC(=O)OCC1OCCC1)N1CCOCC1)CC1CCCCC1 NPSARFACXNWHCR-UHFFFAOYSA-N 0.000 claims description 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 6
- IHNHCTDCYOYYBZ-UHFFFAOYSA-N propyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OCCC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 IHNHCTDCYOYYBZ-UHFFFAOYSA-N 0.000 claims description 6
- IEVZDXDMVLJKIO-UHFFFAOYSA-N 2-methylpropyl n-[n-[1-[(4-cyanopiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC(C)C)NC(C(=O)NC1(CCNCC1)C#N)CC1CCCCC1 IEVZDXDMVLJKIO-UHFFFAOYSA-N 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- HVVJZHKZMVQVSX-UHFFFAOYSA-N benzyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC=1C=CC=CC=1)N1CCOCC1)CC1CCCCC1 HVVJZHKZMVQVSX-UHFFFAOYSA-N 0.000 claims description 5
- VCNMFGFEKWKTOR-UHFFFAOYSA-N ethyl N-[N-[1-[(4-cyanopiperidin-4-yl)-(1-phenylethyl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-C-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C(C)OC(N=C(N1CCOCC1)NC(CC1CCCCC1)C(N(C1(CCNCC1)C#N)C(C)C1=CC=CC=C1)=O)=O VCNMFGFEKWKTOR-UHFFFAOYSA-N 0.000 claims description 5
- MDVBSHZGAIBSIX-UHFFFAOYSA-N ethyl N-[N-[1-[(4-cyanopiperidin-4-yl)-(1-phenylethyl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-C-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C(C)OC(N=C(N1CCOCC1)NC(CC(C)(C)C)C(N(C1(CCNCC1)C#N)C(C)C1=CC=CC=C1)=O)=O MDVBSHZGAIBSIX-UHFFFAOYSA-N 0.000 claims description 5
- YGJSMTMKNPTLBY-UHFFFAOYSA-N ethyl N-[N-[1-[[3-cyano-1-(2-methylpropyl)piperidin-3-yl]amino]-4,4-dimethyl-1-oxopentan-2-yl]-C-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OCC)=NC(CC(C)(C)C)C(=O)NC1(C#N)CCCN(CC(C)C)C1 YGJSMTMKNPTLBY-UHFFFAOYSA-N 0.000 claims description 5
- HTIYHXKBYXHKGL-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-(3,3,5-trimethyl-6-azabicyclo[3.2.1]octan-6-yl)carbonimidoyl]carbamate Chemical compound C1C(CC(C)(C)C2)CC2(C)N1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 HTIYHXKBYXHKGL-UHFFFAOYSA-N 0.000 claims description 5
- GMVNGUPYOGNBGP-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-(4-ethylpiperazin-1-yl)carbonimidoyl]carbamate Chemical compound C1CN(CC)CCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 GMVNGUPYOGNBGP-UHFFFAOYSA-N 0.000 claims description 5
- LYEYZYJAQNGSGN-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-[2-(methoxymethyl)morpholin-4-yl]carbonimidoyl]carbamate Chemical compound C1COC(COC)CN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 LYEYZYJAQNGSGN-UHFFFAOYSA-N 0.000 claims description 5
- QTOOXYCJACWLLZ-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-pyrrolidin-1-ylcarbonimidoyl]carbamate Chemical compound C1CCCN1C(NC(=O)OCC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 QTOOXYCJACWLLZ-UHFFFAOYSA-N 0.000 claims description 5
- KUMWZAHEWBMAQH-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-3-cyclooctyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC)N1CCOCC1)CC1CCCCCCC1 KUMWZAHEWBMAQH-UHFFFAOYSA-N 0.000 claims description 5
- FPSMOQZMUJVXNP-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-[(5,6-difluoro-3-oxoisoindol-1-yl)amino]propanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C1C2=CC(F)=C(F)C=C2C(=O)N1)CC1CCCCC1 FPSMOQZMUJVXNP-UHFFFAOYSA-N 0.000 claims description 5
- OVBGKRFWQCOJNK-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-3-cycloheptyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]propanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(N=C1C=2C=CC=CC=2OC(=O)N1)CC1CCCCCC1 OVBGKRFWQCOJNK-UHFFFAOYSA-N 0.000 claims description 5
- CBXRWYGDRQIQME-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-5,5-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]hexanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CCC(C)(C)C)N=C1C(C=CC=C2)=C2OC(=O)N1 CBXRWYGDRQIQME-UHFFFAOYSA-N 0.000 claims description 5
- OIOBPEVCFRKKIJ-UHFFFAOYSA-N n-[4-cyano-1-(3,3-dimethylbutyl)piperidin-4-yl]-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound C1CN(CCC(C)(C)C)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NC(=O)OC2=C1C=CC=C2 OIOBPEVCFRKKIJ-UHFFFAOYSA-N 0.000 claims description 5
- ABSZKQGIRLBSQX-UHFFFAOYSA-N 2-[(6-chloro-2-oxo-1,3-benzoxazin-4-yl)amino]-n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethylpentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C1C(C=C(Cl)C=C2)=C2OC(=O)N1 ABSZKQGIRLBSQX-UHFFFAOYSA-N 0.000 claims description 4
- DNLPSABETBFDMW-UHFFFAOYSA-N 2-methoxyethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C(NC(=O)OCCOC)N1CCOCC1 DNLPSABETBFDMW-UHFFFAOYSA-N 0.000 claims description 4
- JXOJYAIANJCVBL-UHFFFAOYSA-N 3-tert-butylsulfanyl-n-(4-cyano-1-propylpiperidin-4-yl)-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]propanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CSC(C)(C)C)N=C1C(C=CC=C2)=C2OC(=O)N1 JXOJYAIANJCVBL-UHFFFAOYSA-N 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- HOMSKKBRDAIHJN-UHFFFAOYSA-N benzyl 3-cyano-3-[[4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanoyl]amino]azepane-1-carboxylate Chemical compound N=1C(=O)OC=2C=CC=CC=2C=1NC(CC(C)(C)C)C(=O)NC(C1)(C#N)CCCCN1C(=O)OCC1=CC=CC=C1 HOMSKKBRDAIHJN-UHFFFAOYSA-N 0.000 claims description 4
- ZARYBYZMCJBBOO-UHFFFAOYSA-N ethyl n-[c-(4-acetylpiperazin-1-yl)-n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]carbonimidoyl]carbamate Chemical compound C1CN(C(C)=O)CCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 ZARYBYZMCJBBOO-UHFFFAOYSA-N 0.000 claims description 4
- WTHNICQEBRCWFU-UHFFFAOYSA-N ethyl n-[c-(4-carbamoylpiperidin-1-yl)-n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]carbonimidoyl]carbamate Chemical compound C1CC(C(N)=O)CCN1C(NC(=O)OCC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 WTHNICQEBRCWFU-UHFFFAOYSA-N 0.000 claims description 4
- WWFCGPKTNPWGOC-UHFFFAOYSA-N ethyl n-[n'-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-n,n-diethylcarbamimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC)N(CC)CC)CC1CCCCC1 WWFCGPKTNPWGOC-UHFFFAOYSA-N 0.000 claims description 4
- UMDIMXOSVYWGRW-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-cyclohexylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(CC1)C1CCCCC1)C#N)CC1CCCCC1 UMDIMXOSVYWGRW-UHFFFAOYSA-N 0.000 claims description 4
- JWWYIBHNWJBXGR-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-(3-oxopiperazin-1-yl)carbonimidoyl]carbamate Chemical compound C1CNC(=O)CN1C(NC(=O)OCC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 JWWYIBHNWJBXGR-UHFFFAOYSA-N 0.000 claims description 4
- YXXVLYHQUPLGGB-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-piperidin-1-ylcarbonimidoyl]carbamate Chemical compound C1CCCCN1C(NC(=O)OCC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 YXXVLYHQUPLGGB-UHFFFAOYSA-N 0.000 claims description 4
- WAPPICFWUASIMU-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-thiomorpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CSCCN1C(NC(=O)OCC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 WAPPICFWUASIMU-UHFFFAOYSA-N 0.000 claims description 4
- YKCSLEBOUCIJHD-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-1-oxo-3-(3,3,5,5-tetramethylcyclohexyl)propan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(NC(=NC(=O)OCC)N1CCOCC1)CC1CC(C)(C)CC(C)(C)C1 YKCSLEBOUCIJHD-UHFFFAOYSA-N 0.000 claims description 4
- UEFOVMJBGSNVDS-UHFFFAOYSA-N ethyl n-[n-[3-benzylsulfanyl-1-[(4-cyano-1-propylpiperidin-4-yl)amino]-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC)N1CCOCC1)CSCC1=CC=CC=C1 UEFOVMJBGSNVDS-UHFFFAOYSA-N 0.000 claims description 4
- NGBXODISXXIFHX-UHFFFAOYSA-N methyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(NC(=O)OC)=NC(CC(C)(C)C)C(=O)NC1(C#N)CCN(C)CC1 NGBXODISXXIFHX-UHFFFAOYSA-N 0.000 claims description 4
- UWNLKDNVYHSNLN-UHFFFAOYSA-N methyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C(NC(=O)OC)N1CCOCC1 UWNLKDNVYHSNLN-UHFFFAOYSA-N 0.000 claims description 4
- FMZRXOGESWQABI-UHFFFAOYSA-N n-(3-cyano-1-propylazepan-3-yl)-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound C1N(CCC)CCCCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NC(=O)OC2=C1C=CC=C2 FMZRXOGESWQABI-UHFFFAOYSA-N 0.000 claims description 4
- UXTHSMZOGDHDKU-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-[(6-fluoro-3-oxoisoindol-1-yl)amino]propanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C1C2=CC(F)=CC=C2C(=O)N1)CC1CCCCC1 UXTHSMZOGDHDKU-UHFFFAOYSA-N 0.000 claims description 4
- OOQPVAVONCQIGE-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-4-cyclohexyl-2-[(6-fluoro-2-oxo-1,3-benzoxazin-4-yl)amino]butanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C1C=2C=C(F)C=CC=2OC(=O)N1)CCC1CCCCC1 OOQPVAVONCQIGE-UHFFFAOYSA-N 0.000 claims description 4
- XFLPEDATBSENFZ-UHFFFAOYSA-N n-(4-cyano-1-propylazepan-4-yl)-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound C1CN(CCC)CCCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NC(=O)OC2=C1C=CC=C2 XFLPEDATBSENFZ-UHFFFAOYSA-N 0.000 claims description 4
- NRIXNHFHMVUNSM-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]-3-(3,3,5,5-tetramethylcyclohexyl)propanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(NC=1C=2C=CC=CC=2OC(=O)N=1)CC1CC(C)(C)CC(C)(C)C1 NRIXNHFHMVUNSM-UHFFFAOYSA-N 0.000 claims description 4
- USOBYZDUWPCVGI-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-2-[(5,6-difluoro-3-oxoisoindol-1-yl)amino]-4,4-dimethylpentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C1C2=CC(F)=C(F)C=C2C(=O)N1 USOBYZDUWPCVGI-UHFFFAOYSA-N 0.000 claims description 4
- AIOCNIVXKFFUTL-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethyl-2-[(6-methyl-2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C1C(C=C(C)C=C2)=C2OC(=O)N1 AIOCNIVXKFFUTL-UHFFFAOYSA-N 0.000 claims description 4
- LSWOFTJJFIOAKP-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-4-cyclohexyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]butanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(N=C1C=2C=CC=CC=2OC(=O)N1)CCC1CCCCC1 LSWOFTJJFIOAKP-UHFFFAOYSA-N 0.000 claims description 4
- UDGBXXQVNSKHAB-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-5-methyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]hexanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CCC(C)C)N=C1C(C=CC=C2)=C2OC(=O)N1 UDGBXXQVNSKHAB-UHFFFAOYSA-N 0.000 claims description 4
- YRYXQCJESJUBJS-UHFFFAOYSA-N 2-methylpropyl n-[n-[1-[[4-cyano-1-[2-(2-methoxyethoxy)ethyl]piperidin-4-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCOCCOC)CCC1(C#N)NC(=O)C(NC(=NC(=O)OCC(C)C)N1CCOCC1)CC1CCCCC1 YRYXQCJESJUBJS-UHFFFAOYSA-N 0.000 claims description 3
- ZMXSIRWNLOFDTM-UHFFFAOYSA-N 3-benzylsulfanyl-n-(4-cyano-1-propylpiperidin-4-yl)-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]propanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(N=C1C=2C=CC=CC=2OC(=O)N1)CSCC1=CC=CC=C1 ZMXSIRWNLOFDTM-UHFFFAOYSA-N 0.000 claims description 3
- JLJIAIVFRSRCIT-UHFFFAOYSA-N 4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanoic acid Chemical compound C1=CC=CC2=C1OC(=O)N=C2NC(CC(C)(C)C)C(O)=O JLJIAIVFRSRCIT-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- CEBGKXMLBXOWHB-UHFFFAOYSA-N benzyl 4-cyano-4-[[3-cyclohexyl-2-[[(ethoxycarbonylamino)-morpholin-4-ylmethylidene]amino]propanoyl]amino]piperidine-1-carboxylate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(CC1)C(=O)OCC=1C=CC=CC=1)C#N)CC1CCCCC1 CEBGKXMLBXOWHB-UHFFFAOYSA-N 0.000 claims description 3
- HYWGJYQHZISBBZ-UHFFFAOYSA-N ethyl 1-[n'-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-n-ethoxycarbonylcarbamimidoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 HYWGJYQHZISBBZ-UHFFFAOYSA-N 0.000 claims description 3
- OCGFHIQEHCEKTN-UHFFFAOYSA-N ethyl 4-[[2-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]iminoethoxycarbonylamino]methyl]piperazine-1-carboxylate Chemical compound C(C)OC(=O)N1CCN(CC1)CNC(=O)OCC=NC(CC1CCCCC1)C(NC1(CCN(CC1)C)C#N)=O OCGFHIQEHCEKTN-UHFFFAOYSA-N 0.000 claims description 3
- NEMSIBSDTAURHL-UHFFFAOYSA-N ethyl n-[c-(azocan-1-yl)-n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]carbonimidoyl]carbamate Chemical compound C1CCCCCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 NEMSIBSDTAURHL-UHFFFAOYSA-N 0.000 claims description 3
- CVIWPCFOUPXXAH-UHFFFAOYSA-N ethyl n-[n'-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-n,n-bis(2-methoxyethyl)carbamimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC)N(CCOC)CCOC)CC1CCCCC1 CVIWPCFOUPXXAH-UHFFFAOYSA-N 0.000 claims description 3
- KYRPHIOZGKDKMB-UHFFFAOYSA-N ethyl n-[n'-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-n-ethyl-n-(2-methoxyethyl)carbamimidoyl]carbamate Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC)N(CC)CCOC)CC1CCCCC1 KYRPHIOZGKDKMB-UHFFFAOYSA-N 0.000 claims description 3
- VAVQUUFNYQBQEW-UHFFFAOYSA-N ethyl n-[n-[1-[(1-benzyl-4-cyanopiperidin-4-yl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(CC(C)(C)C)C(=O)NC(CC1)(C#N)CCN1CC1=CC=CC=C1 VAVQUUFNYQBQEW-UHFFFAOYSA-N 0.000 claims description 3
- UUHNRLMJKSNIQP-UHFFFAOYSA-N ethyl n-[n-[1-[(3-cyano-1-propylpyrrolidin-3-yl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1N(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC(=NC(=O)OCC)N1CCOCC1 UUHNRLMJKSNIQP-UHFFFAOYSA-N 0.000 claims description 3
- JJKQCXJSLOIIHP-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-(4-piperidin-1-ylpiperidin-1-yl)carbonimidoyl]carbamate Chemical compound C1CC(N2CCCCC2)CCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 JJKQCXJSLOIIHP-UHFFFAOYSA-N 0.000 claims description 3
- DXANQFDGIKLLMJ-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-(4-pyrrolidin-1-ylpiperidin-1-yl)carbonimidoyl]carbamate Chemical compound C1CC(N2CCCC2)CCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 DXANQFDGIKLLMJ-UHFFFAOYSA-N 0.000 claims description 3
- DOELBRAHCMEDFW-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-3-(4,4-dipropylcyclohexyl)-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(NC(=NC(=O)OCC)N1CCOCC1)CC1CCC(CCC)(CCC)CC1 DOELBRAHCMEDFW-UHFFFAOYSA-N 0.000 claims description 3
- FFGNSZOKJCMGJG-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(COC(C)(C)C)NC(=NC(=O)OCC)N1CCOCC1 FFGNSZOKJCMGJG-UHFFFAOYSA-N 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- XBGSDIFLBYJEES-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-4-cyclohexyl-2-[(6-methoxy-2-oxo-1,3-benzoxazin-4-yl)amino]butanamide Chemical compound C12=CC(OC)=CC=C2OC(=O)NC1=NC(C(=O)NC1(CCN(C)CC1)C#N)CCC1CCCCC1 XBGSDIFLBYJEES-UHFFFAOYSA-N 0.000 claims description 3
- VAHDZMLDOKKRSY-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-2-[(6-fluoro-3-oxoisoindol-1-yl)amino]-4,4-dimethylpentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C1C2=CC(F)=CC=C2C(=O)N1 VAHDZMLDOKKRSY-UHFFFAOYSA-N 0.000 claims description 3
- XILQQLQZBWUMFT-UHFFFAOYSA-N n-(4-cyanopiperidin-4-yl)-4,4-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]pentanamide Chemical compound N=1C(=O)OC=2C=CC=CC=2C=1NC(CC(C)(C)C)C(=O)NC1(C#N)CCNCC1 XILQQLQZBWUMFT-UHFFFAOYSA-N 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- NARPWKCAVBEINT-UHFFFAOYSA-N 2-[(n-benzyl-c-morpholin-4-ylcarbonimidoyl)amino]-n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexylpropanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=NCC=1C=CC=CC=1)N1CCOCC1)CC1CCCCC1 NARPWKCAVBEINT-UHFFFAOYSA-N 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- QOHIARCVLLWSRB-UHFFFAOYSA-N [N-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-4-cyclohexyl-1-oxobutan-2-yl]-C-morpholin-4-ylcarbonimidoyl]carbamic acid Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(NC(=NC(O)=O)N1CCOCC1)CCC1CCCCC1 QOHIARCVLLWSRB-UHFFFAOYSA-N 0.000 claims description 2
- USMAXWGSNIETCE-UHFFFAOYSA-N ethyl n-[n-[1-[(2-cyano-1,3,4,6,7,8,9,9a-octahydroquinolizin-2-yl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN2CCCCC2CC1(C#N)NC(=O)C(CC(C)(C)C)NC(=NC(=O)OCC)N1CCOCC1 USMAXWGSNIETCE-UHFFFAOYSA-N 0.000 claims description 2
- SOPZYFOQZWMDEK-UHFFFAOYSA-N ethyl n-[n-[1-[(3-cyano-1-ethyl-5,5-dimethylpyrrolidin-3-yl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(CC(C)(C)C)C(=O)NC1(C#N)CN(CC)C(C)(C)C1 SOPZYFOQZWMDEK-UHFFFAOYSA-N 0.000 claims description 2
- BASJVHTWEWTVDK-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-4-methyl-1-oxopentan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)C)NC(=NC(=O)OCC)N1CCOCC1 BASJVHTWEWTVDK-UHFFFAOYSA-N 0.000 claims description 2
- JXLUHBOJJFDKRW-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-5,5-dimethyl-1-oxohexan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CCC(C)(C)C)N=C(NC(=O)OCC)N1CCOCC1 JXLUHBOJJFDKRW-UHFFFAOYSA-N 0.000 claims description 2
- LJCDSGFJJWGZIY-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-6-methyl-1-oxoheptan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CCCC(C)C)N=C(NC(=O)OCC)N1CCOCC1 LJCDSGFJJWGZIY-UHFFFAOYSA-N 0.000 claims description 2
- WPDQNKWUUKJXBC-UHFFFAOYSA-N ethyl n-[n-[3-tert-butylsulfanyl-1-[(4-cyano-1-propylpiperidin-4-yl)amino]-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CSC(C)(C)C)N=C(NC(=O)OCC)N1CCOCC1 WPDQNKWUUKJXBC-UHFFFAOYSA-N 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- HORWGRRUYCJULB-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-2-[[methanesulfonamido(morpholin-4-yl)methylidene]amino]-4,4-dimethylpentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC(=NS(C)(=O)=O)N1CCOCC1 HORWGRRUYCJULB-UHFFFAOYSA-N 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- ZUFPZLMRWZOQOE-UHFFFAOYSA-N 3-(4-tert-butylcyclohexyl)-n-(4-cyano-1-propylpiperidin-4-yl)-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]propanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(NC=1C=2C=CC=CC=2OC(=O)N=1)CC1CCC(C(C)(C)C)CC1 ZUFPZLMRWZOQOE-UHFFFAOYSA-N 0.000 claims 2
- YXODWUCIBYZTIX-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-3-(4,4-dipropylcyclohexyl)-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]propanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(NC=1C=2C=CC=CC=2OC(=O)N=1)CC1CCC(CCC)(CCC)CC1 YXODWUCIBYZTIX-UHFFFAOYSA-N 0.000 claims 2
- MFQFVBPJSJEIAP-UHFFFAOYSA-N 2-[[(4-cyanoanilino)-morpholin-4-ylmethylidene]amino]-n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethylpentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC(N1CCOCC1)=NC1=CC=C(C#N)C=C1 MFQFVBPJSJEIAP-UHFFFAOYSA-N 0.000 claims 1
- CFDXXGHMRPSGGS-UHFFFAOYSA-N 4,4-dimethyl-2-[(2-oxo-1h-quinazolin-4-yl)amino]pentanoic acid Chemical compound C1=CC=C2C(NC(CC(C)(C)C)C(O)=O)=NC(=O)NC2=C1 CFDXXGHMRPSGGS-UHFFFAOYSA-N 0.000 claims 1
- FFCJPXZRMDVYFF-UHFFFAOYSA-N 4-amino-1-(2,2-dimethylpropyl)piperidine-4-carbonitrile Chemical compound CC(C)(C)CN1CCC(N)(C#N)CC1 FFCJPXZRMDVYFF-UHFFFAOYSA-N 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- RFLXWWXIDSLZFG-UHFFFAOYSA-N N-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethylpentanamide Chemical compound CCCN1CCC(CC1)(NC(=O)CCC(C)(C)C)C#N RFLXWWXIDSLZFG-UHFFFAOYSA-N 0.000 claims 1
- CRVSGWSKCYXNNY-UHFFFAOYSA-N ethyl 1-[[2-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]iminoethoxycarbonylamino]methyl]piperidine-3-carboxylate Chemical compound C(C)OC(=O)C1CN(CCC1)CNC(=O)OCC=NC(CC1CCCCC1)C(NC1(CCN(CC1)C)C#N)=O CRVSGWSKCYXNNY-UHFFFAOYSA-N 0.000 claims 1
- CFBNTIMRXJNNQH-UHFFFAOYSA-N ethyl 1-[n'-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-n-ethoxycarbonylcarbamimidoyl]piperidine-3-carboxylate Chemical compound C1CCC(C(=O)OCC)CN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 CFBNTIMRXJNNQH-UHFFFAOYSA-N 0.000 claims 1
- BHCDFAAKNFUBOD-UHFFFAOYSA-N ethyl N-[[3-[1-[(4-cyanopiperidin-4-yl)-(1-phenylethyl)amino]-3-cyclohexyl-1-oxopropan-2-yl]iminomorpholin-4-yl]methylidene]carbamate Chemical compound C(C)OC(N=CN1C(COCC1)=NC(CC1CCCCC1)C(N(C1(CCNCC1)C#N)C(C)C1=CC=CC=C1)=O)=O BHCDFAAKNFUBOD-UHFFFAOYSA-N 0.000 claims 1
- SGXQVKCSGUDWHG-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(N=C(NC(=O)OCC)N1CCOCC1)CC1CCCCC1 SGXQVKCSGUDWHG-UHFFFAOYSA-N 0.000 claims 1
- KUZURGWBGMIYHN-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethyl-2-[[morpholin-4-yl-[4-(trifluoromethyl)anilino]methylidene]amino]pentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC(N1CCOCC1)=NC1=CC=C(C(F)(F)F)C=C1 KUZURGWBGMIYHN-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 139
- 125000003386 piperidinyl group Chemical group 0.000 description 133
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 125
- 229910052757 nitrogen Inorganic materials 0.000 description 122
- 125000002757 morpholinyl group Chemical group 0.000 description 121
- 125000004193 piperazinyl group Chemical group 0.000 description 116
- 125000004433 nitrogen atom Chemical group N* 0.000 description 114
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 107
- 125000004076 pyridyl group Chemical group 0.000 description 102
- 229910052717 sulfur Inorganic materials 0.000 description 102
- 125000002883 imidazolyl group Chemical group 0.000 description 101
- 125000000335 thiazolyl group Chemical group 0.000 description 98
- 125000000714 pyrimidinyl group Chemical group 0.000 description 97
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 96
- 125000002971 oxazolyl group Chemical group 0.000 description 94
- 150000003457 sulfones Chemical class 0.000 description 90
- 150000003462 sulfoxides Chemical class 0.000 description 90
- 125000004434 sulfur atom Chemical group 0.000 description 90
- 125000001544 thienyl group Chemical group 0.000 description 83
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 83
- 125000003118 aryl group Chemical group 0.000 description 81
- 125000004043 oxo group Chemical group O=* 0.000 description 81
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 76
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 76
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 74
- 125000001424 substituent group Chemical group 0.000 description 72
- 125000002541 furyl group Chemical group 0.000 description 64
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 63
- 125000001041 indolyl group Chemical group 0.000 description 61
- 125000003373 pyrazinyl group Chemical group 0.000 description 54
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 53
- 125000001624 naphthyl group Chemical group 0.000 description 50
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 48
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 47
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 46
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 44
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 43
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 42
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 125000000623 heterocyclic group Chemical group 0.000 description 39
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 39
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 39
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 125000001153 fluoro group Chemical group F* 0.000 description 38
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 38
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 37
- 229910052736 halogen Inorganic materials 0.000 description 36
- 239000000203 mixture Substances 0.000 description 36
- 150000003857 carboxamides Chemical class 0.000 description 35
- 150000002367 halogens Chemical class 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 32
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 32
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 32
- 229910052739 hydrogen Inorganic materials 0.000 description 30
- 125000000168 pyrrolyl group Chemical group 0.000 description 30
- 239000007787 solid Substances 0.000 description 30
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 29
- 239000001257 hydrogen Substances 0.000 description 29
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 26
- 125000003831 tetrazolyl group Chemical group 0.000 description 26
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 25
- 125000001425 triazolyl group Chemical group 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 108090000613 Cathepsin S Proteins 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 125000004093 cyano group Chemical group *C#N 0.000 description 24
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 125000004104 aryloxy group Chemical group 0.000 description 23
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 22
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 22
- 125000004432 carbon atom Chemical group C* 0.000 description 21
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 20
- 102100035654 Cathepsin S Human genes 0.000 description 20
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 19
- 125000001309 chloro group Chemical group Cl* 0.000 description 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 18
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 18
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 17
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 16
- 108090000625 Cathepsin K Proteins 0.000 description 16
- 102000004171 Cathepsin K Human genes 0.000 description 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 125000005239 aroylamino group Chemical group 0.000 description 15
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 125000003435 aroyl group Chemical group 0.000 description 14
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 description 13
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 13
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 12
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 description 12
- 125000005110 aryl thio group Chemical group 0.000 description 12
- JWJRTTQZJDDBBU-UHFFFAOYSA-N cyano(nitrocarbonyl)carbamic acid Chemical compound OC(=O)N(C#N)C(=O)[N+]([O-])=O JWJRTTQZJDDBBU-UHFFFAOYSA-N 0.000 description 12
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 239000004365 Protease Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 11
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 10
- HUJRNKXVLKUXTP-UHFFFAOYSA-N 2-amino-n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexylpropanamide;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCC1(C#N)NC(=O)C(N)CC1CCCCC1 HUJRNKXVLKUXTP-UHFFFAOYSA-N 0.000 description 10
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 10
- DXNQLZJOTVNBOZ-UHFFFAOYSA-N [O]C(=O)Nc1ccccc1 Chemical group [O]C(=O)Nc1ccccc1 DXNQLZJOTVNBOZ-UHFFFAOYSA-N 0.000 description 10
- 125000005333 aroyloxy group Chemical group 0.000 description 10
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 125000003725 azepanyl group Chemical group 0.000 description 9
- 125000002393 azetidinyl group Chemical group 0.000 description 9
- 239000000460 chlorine Chemical group 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000011737 fluorine Substances 0.000 description 9
- 108010028930 invariant chain Proteins 0.000 description 9
- 125000000842 isoxazolyl group Chemical group 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 125000006603 (C1-C3) alkylaminosulfonyl group Chemical group 0.000 description 8
- 125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 description 8
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 8
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 229910052700 potassium Inorganic materials 0.000 description 8
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 8
- 125000002098 pyridazinyl group Chemical group 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 8
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 7
- 125000003551 oxepanyl group Chemical group 0.000 description 7
- 125000003566 oxetanyl group Chemical group 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 7
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 6
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 102000005600 Cathepsins Human genes 0.000 description 6
- 108010084457 Cathepsins Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 150000001718 carbodiimides Chemical class 0.000 description 6
- 235000011089 carbon dioxide Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 5
- VBEJRJPHNPIURV-UHFFFAOYSA-N 3-chloro-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC=C2C(Cl)=NS(=O)(=O)C2=C1 VBEJRJPHNPIURV-UHFFFAOYSA-N 0.000 description 5
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 108090000610 Cathepsin F Proteins 0.000 description 5
- 102000004176 Cathepsin F Human genes 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 5
- 239000005909 Kieselgur Substances 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 230000008105 immune reaction Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 5
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 108090000712 Cathepsin B Proteins 0.000 description 4
- 102000004225 Cathepsin B Human genes 0.000 description 4
- 108090000624 Cathepsin L Proteins 0.000 description 4
- 102000004172 Cathepsin L Human genes 0.000 description 4
- 229940122805 Cathepsin S inhibitor Drugs 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- GJSLGIVNGKJHRG-UHFFFAOYSA-N ethyl n-(morpholine-4-carbothioyl)carbamate Chemical compound CCOC(=O)NC(=S)N1CCOCC1 GJSLGIVNGKJHRG-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- BXFMSUKIEMFWDH-UHFFFAOYSA-N 2-amino-n-(3-cyano-1-pentan-3-ylpyrrolidin-3-yl)-3-cyclohexylpropanamide;dihydrochloride Chemical compound Cl.Cl.C1N(C(CC)CC)CCC1(C#N)NC(=O)C(N)CC1CCCCC1 BXFMSUKIEMFWDH-UHFFFAOYSA-N 0.000 description 3
- DZUASBBOIAGCBE-UHFFFAOYSA-N 2-amino-n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexylpropanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N)CC1CCCCC1 DZUASBBOIAGCBE-UHFFFAOYSA-N 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- UUOXCNPCUOAGAY-UHFFFAOYSA-N 3-phenyl-3-sulfanylidenepropanamide Chemical compound NC(=O)CC(=S)C1=CC=CC=C1 UUOXCNPCUOAGAY-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- ZOWWPFBCRLKWII-UHFFFAOYSA-N s-cyano n,n-diethylcarbamothioate Chemical compound CCN(CC)C(=O)SC#N ZOWWPFBCRLKWII-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 description 2
- RASGVORPWAYILQ-UHFFFAOYSA-N 1-azabicyclo[3.2.2]nonane Chemical compound C1CC2CCN1CCC2 RASGVORPWAYILQ-UHFFFAOYSA-N 0.000 description 2
- PRFUJBMOTAXNJV-UHFFFAOYSA-N 2,2,3-trimethylbutanal Chemical compound CC(C)C(C)(C)C=O PRFUJBMOTAXNJV-UHFFFAOYSA-N 0.000 description 2
- VYRLTBTWRMMUBK-UHFFFAOYSA-N 2-amino-n-(4-cyano-1-propylpiperidin-4-yl)-3-cyclohexylpropanamide;dihydrochloride Chemical compound Cl.Cl.C1CN(CCC)CCC1(C#N)NC(=O)C(N)CC1CCCCC1 VYRLTBTWRMMUBK-UHFFFAOYSA-N 0.000 description 2
- ULUAEZRBXZKOGD-UHFFFAOYSA-N 2-amino-n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethylpentanamide Chemical compound CCCN1CCC(C#N)(NC(=O)C(N)CC(C)(C)C)CC1 ULUAEZRBXZKOGD-UHFFFAOYSA-N 0.000 description 2
- GRNSBKYVCZORDP-UHFFFAOYSA-N 2-amino-n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethylpentanamide;dihydrochloride Chemical compound Cl.Cl.CCCN1CCC(C#N)(NC(=O)C(N)CC(C)(C)C)CC1 GRNSBKYVCZORDP-UHFFFAOYSA-N 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- LTQBUWVDIKUNHJ-UHFFFAOYSA-N 2-thia-5-azabicyclo[2.2.1]heptane Chemical compound C1SC2CNC1C2 LTQBUWVDIKUNHJ-UHFFFAOYSA-N 0.000 description 2
- VGPCMCBHKUPSCE-UHFFFAOYSA-N 3-amino-5,6-difluoroisoindol-1-one Chemical compound C1=C(F)C(F)=CC2=C1C(=O)NC2=N VGPCMCBHKUPSCE-UHFFFAOYSA-N 0.000 description 2
- MMBYJYAFFGKUDC-UHFFFAOYSA-N 3-aminoisoindol-1-one Chemical compound C1=CC=C2C(N)=NC(=O)C2=C1 MMBYJYAFFGKUDC-UHFFFAOYSA-N 0.000 description 2
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N CH2-hydantoin Natural products O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical group OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- SXSDVAQMOJWYEM-UHFFFAOYSA-N [(3-ethoxy-4-methoxy-2-propoxyphenyl)-phenoxy-propan-2-yloxymethyl] hypofluorite Chemical group CCCOC1=C(OCC)C(OC)=CC=C1C(OF)(OC(C)C)OC1=CC=CC=C1 SXSDVAQMOJWYEM-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000005219 aminonitrile group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- 125000005883 dithianyl group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- GNHNFRXYYSBSAW-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1COCCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 GNHNFRXYYSBSAW-UHFFFAOYSA-N 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- MGGGPLBTQHMRCM-UHFFFAOYSA-N formic acid;isothiocyanatoethane Chemical compound OC=O.CCN=C=S MGGGPLBTQHMRCM-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 125000006301 indolyl methyl group Chemical group 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PPXUHEORWJQRHJ-UHFFFAOYSA-N isovaleric acid ethyl ester Natural products CCOC(=O)CC(C)C PPXUHEORWJQRHJ-UHFFFAOYSA-N 0.000 description 2
- 125000003971 isoxazolinyl group Chemical group 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- AIHUXGASDKGJMP-UHFFFAOYSA-N methyl n-(ethylcarbamoyl)benzenecarboximidate Chemical compound CCNC(=O)N=C(OC)C1=CC=CC=C1 AIHUXGASDKGJMP-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- MQYGOEYNYUWZKF-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-[[(ethylcarbamoylamino)-phenylmethylidene]amino]propanamide Chemical compound C=1C=CC=CC=1C(=NC(=O)NCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 MQYGOEYNYUWZKF-UHFFFAOYSA-N 0.000 description 2
- OFSJRBXHLQDARP-UHFFFAOYSA-N n-(4-fluorobenzenecarbothioyl)acetamide Chemical compound CC(=O)NC(=S)C1=CC=C(F)C=C1 OFSJRBXHLQDARP-UHFFFAOYSA-N 0.000 description 2
- WODDLVJANGATSM-UHFFFAOYSA-N n-(4-methoxybenzenecarbothioyl)acetamide Chemical compound COC1=CC=C(C(=S)NC(C)=O)C=C1 WODDLVJANGATSM-UHFFFAOYSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 2
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- RJURZNIROPGYIR-UHFFFAOYSA-N (1-carboxy-3,3,4-trimethylpentyl)azanium;chloride Chemical compound Cl.CC(C)C(C)(C)CC(N)C(O)=O RJURZNIROPGYIR-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 1
- LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 1
- 125000006563 (C1-3) alkylaminocarbonyl group Chemical group 0.000 description 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006681 (C2-C10) alkylene group Chemical group 0.000 description 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- PEHDFSFYZKSKGH-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrimidin-2-amine Chemical compound NC1=NCCCN1 PEHDFSFYZKSKGH-UHFFFAOYSA-N 0.000 description 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 description 1
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LCCAJUKZSCLLHG-UHFFFAOYSA-N 2,2,3-trimethylbutan-1-ol Chemical compound CC(C)C(C)(C)CO.CC(C)C(C)(C)CO LCCAJUKZSCLLHG-UHFFFAOYSA-N 0.000 description 1
- JUUBFHLPTCPVBO-UHFFFAOYSA-N 2,2-dimethylpropyl carbonochloridate Chemical compound CC(C)(C)COC(Cl)=O JUUBFHLPTCPVBO-UHFFFAOYSA-N 0.000 description 1
- PIJVAQKYUGAAPM-UHFFFAOYSA-N 2,2-dimethylpropyl n-(sulfanylidenemethylidene)carbamate Chemical compound CC(C)(C)COC(=O)N=C=S PIJVAQKYUGAAPM-UHFFFAOYSA-N 0.000 description 1
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 description 1
- 125000006183 2,4-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])*)C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006184 2,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DONZLMCYVTVOHV-UHFFFAOYSA-N 2-[[acetamido(phenyl)methylidene]amino]-n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexylpropanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=NC(C)=O)C=1C=CC=CC=1)CC1CCCCC1 DONZLMCYVTVOHV-UHFFFAOYSA-N 0.000 description 1
- ADYFDYZPELWFGC-UHFFFAOYSA-N 2-[[acetamido-(4-fluorophenyl)methylidene]amino]-n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexylpropanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=NC(C)=O)C=1C=CC(F)=CC=1)CC1CCCCC1 ADYFDYZPELWFGC-UHFFFAOYSA-N 0.000 description 1
- IJLWAVHDGSFYKX-UHFFFAOYSA-N 2-[[acetamido-(4-methoxyphenyl)methylidene]amino]-n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexylpropanamide Chemical compound C1=CC(OC)=CC=C1C(=NC(C)=O)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 IJLWAVHDGSFYKX-UHFFFAOYSA-N 0.000 description 1
- QAYDVSCGSOYAKN-UHFFFAOYSA-N 2-[benzenecarboximidoyl(cyano)amino]-n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexylpropanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(N(C#N)C(=N)C=1C=CC=CC=1)CC1CCCCC1 QAYDVSCGSOYAKN-UHFFFAOYSA-N 0.000 description 1
- NXMWQXDROCRTRN-UHFFFAOYSA-N 2-amino-n-(3-cyano-1-cyclohexylpyrrolidin-3-yl)-3-cyclohexylpropanamide;dihydrochloride Chemical compound Cl.Cl.C1CN(C2CCCCC2)CC1(C#N)NC(=O)C(N)CC1CCCCC1 NXMWQXDROCRTRN-UHFFFAOYSA-N 0.000 description 1
- QLFRSWULVIELBY-UHFFFAOYSA-N 2-amino-n-(4-cyano-1-propylpiperidin-4-yl)-5,5-dimethylhexanamide Chemical compound CCCN1CCC(C#N)(NC(=O)C(N)CCC(C)(C)C)CC1 QLFRSWULVIELBY-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- CGFMLBSNHNWJAW-UHFFFAOYSA-N 2-chloro-4,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=C(F)C=C1Cl CGFMLBSNHNWJAW-UHFFFAOYSA-N 0.000 description 1
- FZRBTBCCMVNZBD-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC=NC(Cl)=N1 FZRBTBCCMVNZBD-UHFFFAOYSA-N 0.000 description 1
- HXVQPZSXXYOZMP-UHFFFAOYSA-N 2-chloropyrimidine-4-carbonitrile Chemical compound ClC1=NC=CC(C#N)=N1 HXVQPZSXXYOZMP-UHFFFAOYSA-N 0.000 description 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- 125000006494 2-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
- LTNUSYNQZJZUSY-UHFFFAOYSA-N 3,3-dimethylbutanal Chemical compound CC(C)(C)CC=O LTNUSYNQZJZUSY-UHFFFAOYSA-N 0.000 description 1
- 125000004911 3,3-dimethylbutylamino group Chemical group CC(CCN*)(C)C 0.000 description 1
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 125000006185 3,4-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000006186 3,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C([H])=C1C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FMNWPBFQLPJWAM-UHFFFAOYSA-N 3-cyclohexylpropanamide Chemical compound NC(=O)CCC1CCCCC1 FMNWPBFQLPJWAM-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
- GKFZBGLUEBXSBF-UHFFFAOYSA-N 4-amino-1-benzylpiperidine-4-carbonitrile Chemical compound C1CC(N)(C#N)CCN1CC1=CC=CC=C1 GKFZBGLUEBXSBF-UHFFFAOYSA-N 0.000 description 1
- HUTRESLXFRPBOW-UHFFFAOYSA-N 4-amino-1-methylpiperidine-4-carbonitrile Chemical compound CN1CCC(N)(C#N)CC1 HUTRESLXFRPBOW-UHFFFAOYSA-N 0.000 description 1
- YRQZAUSIVGMFNN-UHFFFAOYSA-N 4-aminopiperidine-4-carbonitrile Chemical compound N#CC1(N)CCNCC1 YRQZAUSIVGMFNN-UHFFFAOYSA-N 0.000 description 1
- CMZNWOLWNXCCJW-UHFFFAOYSA-N 4-chloro-1,3-benzoxazin-2-one Chemical compound C1=CC=CC2=C1OC(=O)N=C2Cl CMZNWOLWNXCCJW-UHFFFAOYSA-N 0.000 description 1
- KRHIRJLGBOGLNS-UHFFFAOYSA-N 4-chloro-3h-quinazolin-2-one Chemical compound C1=CC=C2C(Cl)=NC(=O)NC2=C1 KRHIRJLGBOGLNS-UHFFFAOYSA-N 0.000 description 1
- VQFOHZWOKJQOGO-UHFFFAOYSA-N 4-fluorobenzenecarbothioamide Chemical compound NC(=S)C1=CC=C(F)C=C1 VQFOHZWOKJQOGO-UHFFFAOYSA-N 0.000 description 1
- WKWVTPKUHJOVTI-UHFFFAOYSA-N 4-methoxybenzenecarbothioamide Chemical compound COC1=CC=C(C(N)=S)C=C1 WKWVTPKUHJOVTI-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- SKBCMXHEYKBYOC-UHFFFAOYSA-N 5,5-dimethyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]hexanoic acid Chemical compound C1=CC=CC2=C1OC(=O)N=C2NC(CCC(C)(C)C)C(O)=O SKBCMXHEYKBYOC-UHFFFAOYSA-N 0.000 description 1
- FRRTYHLCHQZMIN-UHFFFAOYSA-N 5-methyl-2-[(2-oxo-1,3-benzoxazin-4-yl)amino]hexanoic acid Chemical compound C1=CC=CC2=C1OC(=O)N=C2NC(CCC(C)C)C(O)=O FRRTYHLCHQZMIN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- MBCKBXLMJVWCEG-UHFFFAOYSA-N C(C)OC(=O)N1CCN(CC1)C=NC(=O)OCCNC(CC1CCCCC1)C(NC1(CCN(CC1)C)C#N)=O Chemical compound C(C)OC(=O)N1CCN(CC1)C=NC(=O)OCCNC(CC1CCCCC1)C(NC1(CCN(CC1)C)C#N)=O MBCKBXLMJVWCEG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- FUYUKMZUVAYSIM-UHFFFAOYSA-N Cl.Cl.CCCN1CCC(C#N)(NC(=O)C(N)CC(C)(C)C(C)C)CC1 Chemical compound Cl.Cl.CCCN1CCC(C#N)(NC(=O)C(N)CC(C)(C)C(C)C)CC1 FUYUKMZUVAYSIM-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Chemical group 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical compound NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 description 1
- TVIUSKXXXZSVJU-UHFFFAOYSA-N [dichloro(phenoxy)methoxy]benzene Chemical compound C=1C=CC=CC=1OC(Cl)(Cl)OC1=CC=CC=C1 TVIUSKXXXZSVJU-UHFFFAOYSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- OAYRYNVEFFWSHK-UHFFFAOYSA-N carsalam Chemical compound C1=CC=C2OC(=O)NC(=O)C2=C1 OAYRYNVEFFWSHK-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- SLIKWVTWIGHFJE-UHFFFAOYSA-N diphenoxymethylidenecyanamide Chemical compound C=1C=CC=CC=1OC(=NC#N)OC1=CC=CC=C1 SLIKWVTWIGHFJE-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- QEIVPDRGIDPMTE-UHFFFAOYSA-N ethyl 2,2,3-trimethylbutanoate Chemical compound CCOC(=O)C(C)(C)C(C)C QEIVPDRGIDPMTE-UHFFFAOYSA-N 0.000 description 1
- DTRSYXUXXDLSEB-UHFFFAOYSA-N ethyl 2-[4-[n'-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-n-ethoxycarbonylcarbamimidoyl]piperazin-1-yl]acetate Chemical compound C1CN(CC(=O)OCC)CCN1C(NC(=O)OCC)=NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 DTRSYXUXXDLSEB-UHFFFAOYSA-N 0.000 description 1
- CSIYCGHLZZHLPT-UHFFFAOYSA-N ethyl 2-formamido-4,4,5-trimethylhex-2-enoate Chemical compound CCOC(=O)C(NC=O)=CC(C)(C)C(C)C CSIYCGHLZZHLPT-UHFFFAOYSA-N 0.000 description 1
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 1
- JDSIPSCWXKWJKE-UHFFFAOYSA-N ethyl 4-[n'-[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]-n-ethoxycarbonylcarbamimidoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 JDSIPSCWXKWJKE-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- ACZCLKQPCHYRPR-UHFFFAOYSA-N ethyl n-[[[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-piperidin-1-ylmethyl]carbamate Chemical compound C1CCCCN1C(NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 ACZCLKQPCHYRPR-UHFFFAOYSA-N 0.000 description 1
- DGVQAJJUCVTHQL-UHFFFAOYSA-N ethyl n-[[[1-[(4-cyano-1-methylpiperidin-4-yl)amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-pyrrolidin-1-ylmethyl]carbamate Chemical compound C1CCCN1C(NC(=O)OCC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 DGVQAJJUCVTHQL-UHFFFAOYSA-N 0.000 description 1
- YNKYXQLSFDHMGR-UHFFFAOYSA-N ethyl n-[n-[1-[(4-cyano-1-propylpiperidin-4-yl)amino]-4,4-dimethyl-1-oxopentan-2-yl]-c-morpholin-4-ylcarbonimidoyl]carbamate Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)N=C(NC(=O)OCC)N1CCOCC1 YNKYXQLSFDHMGR-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000012178 germinal center formation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- DYMKGQRODFWYQX-UHFFFAOYSA-N methyl 2-aminoprop-2-enoate Chemical compound COC(=O)C(N)=C DYMKGQRODFWYQX-UHFFFAOYSA-N 0.000 description 1
- AYXSLWFGIGSIDJ-UHFFFAOYSA-N methyl 2-chloro-4,5-difluorobenzoate Chemical compound COC(=O)C1=CC(F)=C(F)C=C1Cl AYXSLWFGIGSIDJ-UHFFFAOYSA-N 0.000 description 1
- YDQRRCIXAPHXNP-UHFFFAOYSA-N methyl 2-cyano-4,5-difluorobenzoate Chemical compound COC(=O)C1=CC(F)=C(F)C=C1C#N YDQRRCIXAPHXNP-UHFFFAOYSA-N 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical compound COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- NWXXBPZCLRQIFG-UHFFFAOYSA-N methyl 3-(4,4-dimethylcyclohexen-1-yl)-2-(phenylmethoxycarbonylamino)prop-2-enoate Chemical compound C=1CC(C)(C)CCC=1C=C(C(=O)OC)NC(=O)OCC1=CC=CC=C1 NWXXBPZCLRQIFG-UHFFFAOYSA-N 0.000 description 1
- CLTYKEQQRFBTLE-UHFFFAOYSA-N methyl 5,5-dimethyl-2-(phenylmethoxycarbonylamino)hex-2-enoate Chemical compound CC(C)(C)CC=C(C(=O)OC)NC(=O)OCC1=CC=CC=C1 CLTYKEQQRFBTLE-UHFFFAOYSA-N 0.000 description 1
- SISQKQNJHCDULL-UHFFFAOYSA-N methyl benzenecarboximidate Chemical compound COC(=N)C1=CC=CC=C1 SISQKQNJHCDULL-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- OFCCYDUUBNUJIB-UHFFFAOYSA-N n,n-diethylcarbamoyl chloride Chemical compound CCN(CC)C(Cl)=O OFCCYDUUBNUJIB-UHFFFAOYSA-N 0.000 description 1
- QEZHCHUTBFWLFZ-UHFFFAOYSA-N n-(3-cyano-1-cyclohexylpyrrolidin-3-yl)-3-cyclohexyl-2-[(1,1-dioxo-1,2-benzothiazol-3-yl)amino]propanamide Chemical compound C1CCCCC1CC(NC=1C2=CC=CC=C2S(=O)(=O)N=1)C(=O)NC(C1)(C#N)CCN1C1CCCCC1 QEZHCHUTBFWLFZ-UHFFFAOYSA-N 0.000 description 1
- PCBLWPWXWJVPIO-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-2-[(4-cyanopyrimidin-2-yl)amino]-3-cyclohexylpropanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC=1N=C(C=CN=1)C#N)CC1CCCCC1 PCBLWPWXWJVPIO-UHFFFAOYSA-N 0.000 description 1
- XPXHOALPPWONKL-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-(diethylcarbamoylcarbamothioylamino)propanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC(=S)NC(=O)N(CC)CC)CC1CCCCC1 XPXHOALPPWONKL-UHFFFAOYSA-N 0.000 description 1
- BRPGKJAPNJPMEC-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-[(1,1-dioxo-1,2-benzothiazol-3-yl)amino]propanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC=1C2=CC=CC=C2S(=O)(=O)N=1)CC1CCCCC1 BRPGKJAPNJPMEC-UHFFFAOYSA-N 0.000 description 1
- QXVSRPLPPXJLBB-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-[(3-oxoisoindol-1-yl)amino]propanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC=1C2=CC=CC=C2C(=O)N=1)CC1CCCCC1 QXVSRPLPPXJLBB-UHFFFAOYSA-N 0.000 description 1
- OCINBPTXHFYLEG-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-[[(diethylcarbamoylamino)-morpholin-4-ylmethylidene]amino]propanamide Chemical compound C1COCCN1C(=NC(=O)N(CC)CC)NC(C(=O)NC1(CCN(C)CC1)C#N)CC1CCCCC1 OCINBPTXHFYLEG-UHFFFAOYSA-N 0.000 description 1
- CYAAUZTVIWMMFF-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)-3-cyclohexyl-2-[[4-(trifluoromethyl)pyrimidin-2-yl]amino]propanamide Chemical compound C1CN(C)CCC1(C#N)NC(=O)C(NC=1N=C(C=CN=1)C(F)(F)F)CC1CCCCC1 CYAAUZTVIWMMFF-UHFFFAOYSA-N 0.000 description 1
- AMJXNMUVBHEQBX-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-2-[(1,1-dioxo-1,2-benzothiazol-3-yl)amino]-4,4-dimethylpentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NS(=O)(=O)C2=CC=CC=C12 AMJXNMUVBHEQBX-UHFFFAOYSA-N 0.000 description 1
- QNPBQGXAFYADEL-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-3-cyclohexyl-2-[(1,1-dioxo-1,2-benzothiazol-3-yl)amino]propanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(NC=1C2=CC=CC=C2S(=O)(=O)N=1)CC1CCCCC1 QNPBQGXAFYADEL-UHFFFAOYSA-N 0.000 description 1
- RPGQMXWMZFRLKF-UHFFFAOYSA-N n-(4-cyano-1-propylpiperidin-4-yl)-4,4-dimethyl-2-[(3-oxoisoindol-1-yl)amino]pentanamide Chemical compound C1CN(CCC)CCC1(C#N)NC(=O)C(CC(C)(C)C)NC1=NC(=O)C2=CC=CC=C12 RPGQMXWMZFRLKF-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Manufacturing & Machinery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Materials Engineering (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Structural Engineering (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/655,351 US6420364B1 (en) | 1999-09-13 | 2000-09-08 | Compound useful as reversible inhibitors of cysteine proteases |
PCT/US2001/008084 WO2002020485A1 (en) | 2000-09-08 | 2001-03-14 | Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20030163A2 true HRP20030163A2 (en) | 2005-04-30 |
Family
ID=24628539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030163A HRP20030163A2 (en) | 2000-09-08 | 2003-03-06 | Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
Country Status (25)
Country | Link |
---|---|
US (10) | US6420364B1 (sh) |
EP (1) | EP1322613A1 (sh) |
JP (1) | JP2004508356A (sh) |
KR (1) | KR20030051644A (sh) |
CN (1) | CN1303067C (sh) |
AU (1) | AU2001245694A1 (sh) |
BG (1) | BG107585A (sh) |
BR (1) | BR0113740A (sh) |
CA (1) | CA2417177A1 (sh) |
CZ (1) | CZ2003603A3 (sh) |
EA (1) | EA005203B1 (sh) |
EE (1) | EE200300093A (sh) |
HK (1) | HK1060565A1 (sh) |
HR (1) | HRP20030163A2 (sh) |
HU (1) | HUP0303934A2 (sh) |
IL (1) | IL154080A0 (sh) |
MX (1) | MXPA03001947A (sh) |
NO (1) | NO20031065D0 (sh) |
NZ (1) | NZ525169A (sh) |
PL (1) | PL361038A1 (sh) |
SK (1) | SK2862003A3 (sh) |
UA (1) | UA73378C2 (sh) |
WO (1) | WO2002020485A1 (sh) |
YU (1) | YU17003A (sh) |
ZA (1) | ZA200301032B (sh) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9723407D0 (en) * | 1997-11-05 | 1998-01-07 | Ciba Geigy Ag | Organic compounds |
AU3731400A (en) * | 1999-03-05 | 2000-09-21 | Trustees Of University Technology Corporation, The | Methods and compositions useful in inhibiting apoptosis |
US6420364B1 (en) * | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
US6773704B1 (en) * | 1999-10-28 | 2004-08-10 | The Brigham And Women's Hospital, Inc. | Methods of treating vascular disease associated with cystatin C deficiency |
GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
EP1383748A2 (en) | 2000-12-22 | 2004-01-28 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as cathepsin inhibitors |
US7030116B2 (en) | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
US7012075B2 (en) * | 2001-03-02 | 2006-03-14 | Merck & Co., Inc. | Cathepsin cysteine protease inhibitors |
US6982263B2 (en) * | 2001-06-08 | 2006-01-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nitriles useful as reversible inhibitors of cysteine proteases |
DE10141650C1 (de) * | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
JP2005504078A (ja) | 2001-09-14 | 2005-02-10 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | カテプシン阻害剤としての新規化合物および組成物 |
JP2005504827A (ja) * | 2001-10-02 | 2005-02-17 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | システインプロテアーゼの可逆性インヒビターとして有用な化合物 |
JP2005508979A (ja) * | 2001-10-29 | 2005-04-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | システインプロテアーゼの可逆性インヒビターとして有用な化合物 |
EP1446392A1 (en) | 2001-11-14 | 2004-08-18 | Aventis Pharmaceuticals, Inc. | Oligopeptides and compositions containing them as cathepsin s inhibitors |
WO2004000838A1 (en) * | 2002-06-24 | 2003-12-31 | Axys Pharmaceuticals, Inc. | Peptidic compounds as cysteine protease inhibitors |
US7326690B2 (en) * | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
US7465745B2 (en) * | 2003-03-13 | 2008-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cathepsin S inhibitors |
US7326719B2 (en) * | 2003-03-13 | 2008-02-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cathepsin S inhibitors |
US7384970B2 (en) * | 2003-03-24 | 2008-06-10 | Irm Llc | Inhibitors of cathepsin S |
US7109243B2 (en) * | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
WO2004089395A2 (en) * | 2003-04-01 | 2004-10-21 | Aventis Pharmaceuticals Inc. | Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease |
JP2006526657A (ja) * | 2003-06-04 | 2006-11-24 | アクシス ファーマシューティカルズ | システインプロテアーゼ阻害剤としてのアミジノ化合物 |
US7173051B2 (en) * | 2003-06-13 | 2007-02-06 | Irm, Llc | Inhibitors of cathepsin S |
US7256207B2 (en) * | 2003-08-20 | 2007-08-14 | Irm Llc | Inhibitors of cathepsin S |
TW200524851A (en) * | 2003-09-18 | 2005-08-01 | Axys Pharm Inc | Haloalkyl containing compounds as cysteine protease inhibitors |
CA2543884A1 (en) * | 2003-10-30 | 2005-05-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Dipeptide-analogue synthesis |
PE20050897A1 (es) * | 2003-12-03 | 2005-11-06 | Glaxo Group Ltd | Nuevos antagonistas del receptor muscarinico m3 de acetilcolina |
JP2007513972A (ja) * | 2003-12-11 | 2007-05-31 | アクシス・ファーマシューティカルズ・インコーポレイテッド | 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンsインヒビターの使用 |
WO2005056529A1 (en) * | 2003-12-12 | 2005-06-23 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
WO2005063742A2 (en) * | 2003-12-23 | 2005-07-14 | Axys Pharmaceuticals, Inc. | Amidino compounds as cysteine protease inhibitors |
WO2006060810A1 (en) * | 2004-12-02 | 2006-06-08 | Schering Aktiengesellschaft | Sulfonamide compounds as cysteine protease inhibitors |
EP1841730A4 (en) * | 2005-01-19 | 2010-10-27 | Merck Frosst Canada Ltd | CATHEPSIN K INHIBITORS AND ATHEROSCLEROSIS |
MX2007011617A (es) | 2005-03-21 | 2008-03-13 | Applera Corp | Compuestos de alfa-cetoamida como inhibidores de la cisteina proteasa. |
EP1866277B1 (en) * | 2005-03-22 | 2014-06-25 | Virobay, Inc. | Sulfonyl containing compounds as cysteine protease inhibitors |
US7282964B2 (en) * | 2005-05-25 | 2007-10-16 | Texas Instruments Incorporated | Circuit for detecting transitions on either of two signal lines referenced at different power supply levels |
US8722708B2 (en) * | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
US8067415B2 (en) * | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
US20100016289A1 (en) * | 2005-11-01 | 2010-01-21 | Kevin Sprott | Compounds Useful as Antagonists of CCR2 |
US8067457B2 (en) * | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
US7531671B2 (en) | 2005-11-01 | 2009-05-12 | Janssen Pharmaceutica N.V. | Dihydroisoindolones as allosteric modulators of glucokinase |
ES2392675T3 (es) * | 2006-06-01 | 2012-12-12 | Sanofi | Nitrilos espirocíclicos como inhibidores de proteasa |
US8652844B2 (en) | 2006-06-13 | 2014-02-18 | The Curators Of The University Of Missouri | Methods for the cryopreservation of animal cells that contain high levels of intracellular lipids |
US8071625B2 (en) * | 2006-08-02 | 2011-12-06 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
US8063082B2 (en) * | 2006-08-02 | 2011-11-22 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
KR101555931B1 (ko) * | 2006-10-04 | 2015-09-30 | 비로베이, 인코포레이티드 | 시스테인 프로테아제 억제제로서의 디플루오로 함유 화합물 |
US7893112B2 (en) | 2006-10-04 | 2011-02-22 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
KR100877394B1 (ko) | 2007-07-11 | 2009-01-07 | 한국화학연구원 | 카보니트릴 화합물을 포함하는 골다공증 및 치은 질환의치료 및 예방을 위한 약제학적 조성물 |
CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
WO2009011871A2 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
US8088793B2 (en) | 2007-08-15 | 2012-01-03 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
CA2709677C (en) | 2007-12-21 | 2017-03-14 | Lin Zhi | Selective androgen receptor modulators (sarms) and uses thereof |
JP5587790B2 (ja) | 2008-01-09 | 2014-09-10 | アミュラ セラピューティクス リミティド | 化合物 |
BRPI0918970A2 (pt) * | 2008-09-05 | 2019-09-24 | Avila Therapeutics Inc | algoritmo para projeto de inibidores irreversíveis |
CA2753205A1 (en) * | 2009-02-19 | 2010-08-26 | Vanderbilt University | Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same |
US8324417B2 (en) | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
SG179172A1 (en) | 2009-09-16 | 2012-04-27 | Avila Therapeutics Inc | Protein kinase conjugates and inhibitors |
MX2012007684A (es) | 2009-12-30 | 2012-10-05 | Avila Therapeutics Inc | Modificacion covalente ligando dirigida de proteina. |
WO2012151319A1 (en) | 2011-05-02 | 2012-11-08 | Virobay, Inc. | Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain |
JP5859000B2 (ja) | 2011-06-07 | 2016-02-10 | 株式会社クレハ | オキセタン化合物の製造方法、アゾリルメチルシクロペンタノール化合物の製造方法、および中間体化合物 |
EP2537532A1 (en) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
DK2780015T3 (en) | 2011-11-18 | 2017-03-27 | Heptares Therapeutics Ltd | M1 MUSCARINRECEPTORAGONISTER |
ES2785313T3 (es) * | 2013-01-15 | 2020-10-06 | Merck Patent Gmbh | Acilguanidinas para el tratamiento de la artrosis |
US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
CN111943848B (zh) * | 2020-08-19 | 2023-05-05 | 苏州旺山旺水生物医药有限公司 | 一种elexacaftor中间体的制备方法及其应用 |
Family Cites Families (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3467691A (en) | 1964-04-22 | 1969-09-16 | Tsutomu Irikura | N-(n-acylaminoacyl)-aminoacetonitriles |
US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
JPS4310619Y1 (sh) | 1967-02-16 | 1968-05-09 | ||
EP0115472A3 (de) | 1983-01-27 | 1985-10-02 | Ciba-Geigy Ag | Pyrrolidinonderivate und Verfahren zu ihrer Herstellung |
US4767202A (en) * | 1984-01-20 | 1988-08-30 | Minolta Camera Kabushiki Kaisha | Objective lens system for optical recording type disks |
JPS61502124A (ja) * | 1984-05-09 | 1986-09-25 | ジ オ−ストラリアン ナシヨナル ユニヴア−シテイ− | 免疫応答の調節方法 |
US4797202A (en) | 1984-09-13 | 1989-01-10 | The Dow Chemical Company | Froth flotation method |
US4737425A (en) * | 1986-06-10 | 1988-04-12 | International Business Machines Corporation | Patterned resist and process |
JPS6358346A (ja) | 1986-08-29 | 1988-03-14 | Fuji Photo Film Co Ltd | カラ−写真現像液組成物及びハロゲン化銀写真感光材料の処理方法 |
US4734425A (en) | 1986-10-17 | 1988-03-29 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs |
US4749715A (en) | 1987-03-02 | 1988-06-07 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted amino prostaglandin analogs |
FR2615104B1 (fr) | 1987-05-14 | 1989-08-18 | Centre Nat Rech Scient | Nouvelle protease de plasmodium falciparum, anticorps diriges contre cette protease, substrats peptidiques specifiques de ladite protease, et leur utilisation comme medicament contre le paludisme |
JPS63301868A (ja) | 1987-06-01 | 1988-12-08 | Nippon Kayaku Co Ltd | N−(2−クロロイソニコチノイル)アミノ酸誘導体およびそれを有効成分とする農園芸用殺菌剤 |
DE3719226A1 (de) | 1987-06-09 | 1988-12-22 | Bayer Ag | (2-cyan-2-oximinoacetyl)-aminosaeure-derivate |
US4971978A (en) | 1987-09-21 | 1990-11-20 | Nadzan Alex M | Derivatives of D-glutamic acid and D-aspartic acid |
EP0314060A3 (en) | 1987-10-26 | 1991-06-19 | Warner-Lambert Company | Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them |
CA1322005C (en) | 1987-11-25 | 1993-09-07 | Robert N. Young | Benzoheterazoles |
US4962117A (en) | 1987-11-25 | 1990-10-09 | Merck Frosst Canada, Inc. | Heterazole dialkanoic acids |
US5004743A (en) | 1987-11-25 | 1991-04-02 | Merck Frosst Canada, Inc. | Pyridyl styrene dialkanoic acids as anti-leukotriene agents |
EP0442878A4 (en) | 1988-04-05 | 1991-10-23 | Abbott Laboratories | Derivatives of tryptophan as cck antagonists |
US5346907A (en) | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
EP0413750A1 (en) | 1988-05-03 | 1991-02-27 | The Upjohn Company | Renin inhibitory peptides containing a substituted phenoxyacetyle group |
DE3827727A1 (de) | 1988-08-16 | 1990-02-22 | Boehringer Ingelheim Kg | Anellierte tetrahydropyridinessigsaeurederivate, verfahren zu deren herstellung und verwendung solcher verbindungen zur kardioprotektion |
EP0374098A3 (de) | 1988-12-15 | 1991-05-02 | Ciba-Geigy Ag | Retrovirale Proteasehemmer |
US5270302A (en) | 1988-12-21 | 1993-12-14 | Abbott Laboratories | Derivatives of tetrapeptides as CCK agonists |
GB8909836D0 (en) | 1989-04-28 | 1989-06-14 | Boots Co Plc | Therapeutic agent |
DE3915755A1 (de) | 1989-05-13 | 1990-11-29 | Bayer Ag | Fungizide mittel sowie substituierte aminosaeureamid-derivate und deren herstellung |
US5504109A (en) | 1989-05-13 | 1996-04-02 | Bayer Aktiengesellschaft | Susbstituted amino acid amide derivatives their preparation and use |
US5196291A (en) | 1989-05-24 | 1993-03-23 | Fuji Photo Film Co., Ltd. | Silver halide photographic material |
JP2658004B2 (ja) | 1989-05-31 | 1997-09-30 | キヤノン株式会社 | 電子写真感光体 |
JPH0462788A (ja) | 1990-06-30 | 1992-02-27 | Toshiba Corp | 電子レンジ |
FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
JPH06145173A (ja) | 1990-08-21 | 1994-05-24 | Fujisawa Pharmaceut Co Ltd | 1−アザビシクロ[3.2.0]ヘプト−2−エン−2−カルボン酸化合物 |
JPH0511439A (ja) | 1990-09-13 | 1993-01-22 | Fuji Photo Film Co Ltd | 光重合性組成物 |
DE4035961A1 (de) | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
AU9042191A (en) | 1990-12-07 | 1992-07-08 | Dyno Industrier A.S. | System for utilization of wave energy |
DE4104257A1 (de) | 1991-02-13 | 1992-08-20 | Boehringer Ingelheim Kg | Verwendung von anellierten tetrahydropyridinessigsaeurederivaten fuer die behandlung neurologischer erkrankungen |
US5461176A (en) | 1991-03-27 | 1995-10-24 | The Du Pont Merck Pharmaceutical Company | Processes for preparing bis-naphthalimides containing amino-acid derived linkers |
US5206249A (en) | 1991-03-27 | 1993-04-27 | Du Pont Merck Pharmaceutical Company | Bis-naphthalimides containing amino-acid derived linkers as anticancer agents |
US5190922A (en) | 1991-06-04 | 1993-03-02 | Abbott Laboratories | Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands |
JPH06510986A (ja) | 1991-06-14 | 1994-12-08 | カイロン コーポレイション | ピコルナウイルスプロテアーゼのインヒビター |
US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
US5298377A (en) | 1991-08-28 | 1994-03-29 | Eastman Kodak Company | Photographic element with 2-equivalent magenta dye-forming coupler and filter dye |
US5215876A (en) | 1991-08-29 | 1993-06-01 | Eastman Kodak Company | Radiographic element with uv absorbation compound in polyester support |
US5204349A (en) | 1991-09-16 | 1993-04-20 | Merck & Co., Inc. | Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists |
JP2947539B2 (ja) | 1991-11-12 | 1999-09-13 | コニカ株式会社 | ハロゲン化銀写真感光材料 |
ES2107557T3 (es) | 1991-12-10 | 1997-12-01 | Shionogi & Co | Derivado de acido hidroxamico a base de sulfonamida aromatica. |
EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
GB9200209D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
US5218123A (en) | 1992-02-18 | 1993-06-08 | Warner-Lambert Company | Didehydrotryptophan derivatives and pharmaceutical use thereof |
US5831002A (en) | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
JPH063787A (ja) | 1992-06-18 | 1994-01-14 | Konica Corp | ハロゲン化銀写真感光材料用固形発色現像処理剤及び該固形発色現像処理剤を用いた処理方法 |
CA2138788A1 (en) | 1992-06-22 | 1994-01-06 | Dietrich Arndts | Ring-closed dihydropyridines and their use in the preparation of pharmaceutical compositions |
FR2694006A1 (fr) | 1992-07-22 | 1994-01-28 | Esteve Labor Dr | Amides dérivés de benzohétérocyles. |
DE4225487A1 (de) | 1992-07-30 | 1994-02-03 | Schering Ag | Interphenylen-bicyclo(3.3.0)octan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
JPH0651451A (ja) | 1992-07-31 | 1994-02-25 | Konica Corp | ハロゲン化銀写真感光材料用固形処理剤 |
JP3168547B2 (ja) | 1992-08-18 | 2001-05-21 | 日本製粉株式会社 | ポテト生地用ミックス、ポテト生地の製造法およびポテト生地を用いたフライ食品 |
JP3283114B2 (ja) | 1992-09-07 | 2002-05-20 | クミアイ化学工業株式会社 | 縮合ヘテロ環誘導体及び農園芸用殺菌剤 |
US5389682A (en) | 1992-09-18 | 1995-02-14 | Warner-Lambert Company | Agents acting at cholecystokinin receptors |
DE4232505A1 (de) | 1992-09-29 | 1994-03-31 | Degussa | Verfahren zur Reduktion von Carbonsäuren oder Carbonsäurederivaten sowie neue Verbindungen |
EP0604182B1 (en) | 1992-12-22 | 2000-10-11 | Eli Lilly And Company | Inhibitors of HIV protease useful for the treatment of Aids |
DE4303145A1 (de) | 1993-01-30 | 1994-08-04 | Schering Ag | Interphenylen-2-Oxabicyclo(2.2.1)heptan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
JP2848232B2 (ja) | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
WO1994021657A1 (en) | 1993-03-18 | 1994-09-29 | Pfizer Inc. | Antibacterial 16-membered ring macrolides containing olefins at c-20 |
JPH08509709A (ja) | 1993-03-29 | 1996-10-15 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | N▲上α▼−メチルアルギニンを含有する血小板糖たんぱく▲II▼b/▲III▼a抑制剤の製造方法およびそれに用いる中間体化合物 |
JPH06340643A (ja) | 1993-04-04 | 1994-12-13 | Nippon Nohyaku Co Ltd | オキサゾ−ル又はチアゾ−ル誘導体及びその製造方法並びに除草剤 |
JP3165760B2 (ja) | 1993-04-12 | 2001-05-14 | 株式会社トクヤマ | 新規化合物 |
US5658885A (en) | 1993-04-27 | 1997-08-19 | The Dupont Merck Pharmaceutical Company | Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes |
EP0648740B1 (en) | 1993-04-28 | 1997-10-08 | Kumiai Chemical Industry Co., Ltd. | Amino acid amide derivative, agrohorticultural bactericide, and production process |
JPH0789951A (ja) | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | インターロイキン−1β転換酵素阻害剤 |
US5514778A (en) | 1993-07-01 | 1996-05-07 | Eli Lilly And Company | Anti-picornaviral agents |
DE4321897A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Schering Agrevo Gmbh | Substituierte Aminosäureamid-Derivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung |
DE4322067A1 (de) | 1993-07-02 | 1995-01-12 | Hoechst Schering Agrevo Gmbh | Acylierte Aminophenylsulfonylharnstoffe; Darstellung und Verwendung als Herbizide und Wachstumsregulatoren |
CH686479A5 (fr) | 1993-08-11 | 1996-04-15 | Nestle Sa | Produit alimentaire a rehydratation rapide et son procede de preparation. |
US5554753A (en) | 1993-08-25 | 1996-09-10 | Indiana University Foundation | Catalytic enantioselective synthesis of α-amino acid derivatives by phase-transfer catalysis |
JPH07101959A (ja) | 1993-09-30 | 1995-04-18 | Sankyo Co Ltd | 1−メチルカルバペネム誘導体 |
AU687449B2 (en) | 1993-10-01 | 1998-02-26 | Aventis Inc. | Inhibitors of beta-amyloid protein production |
IT1270882B (it) | 1993-10-05 | 1997-05-13 | Isagro Srl | Oligopeptidi ad attivita' fungicida |
JP3075657B2 (ja) | 1993-10-15 | 2000-08-14 | 富士写真フイルム株式会社 | 写真用処理組成物及び処理方法 |
AU691201B2 (en) | 1993-11-01 | 1998-05-14 | Japat Ltd. | Endothelin receptor antagonists |
US5486623A (en) | 1993-12-08 | 1996-01-23 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
DE4343528A1 (de) | 1993-12-16 | 1995-06-22 | Schering Ag | Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
IL112759A0 (en) | 1994-02-25 | 1995-05-26 | Khepri Pharmaceuticals Inc | Novel cysteine protease inhibitors |
WO1995024382A1 (en) | 1994-03-10 | 1995-09-14 | G.D. Searle & Co. | L-n6-(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors |
ATE157965T1 (de) | 1994-03-19 | 1997-09-15 | Basf Ag | Fungizide carbamoyloximcarbonsäureamide |
JPH07285931A (ja) | 1994-04-19 | 1995-10-31 | Tokuyama Corp | 新規化合物 |
DE4415049A1 (de) | 1994-04-29 | 1995-11-02 | Hoechst Schering Agrevo Gmbh | Acylierte Aminophenylsulfonylharnstoffe, Verfahren zu deren Herstellung und Verwendung als Herbizide und Wachstumsregulatoren |
DE4419517A1 (de) | 1994-06-03 | 1995-12-07 | Basf Ag | Substituierte 3-Phenylpyrazole |
US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
DE4431467A1 (de) | 1994-09-03 | 1996-03-07 | Basf Ag | Caramoylcarbonsäureamide |
WO1996010559A1 (en) | 1994-10-04 | 1996-04-11 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
JP3933198B2 (ja) | 1994-10-26 | 2007-06-20 | ファルマシア・アンド・アップジョン・カンパニー | フェニルオキサゾリジノン抗菌剤 |
CA2163325A1 (en) | 1994-11-21 | 1996-05-22 | Kaneyoshi Kato | Amine compounds, their production and use |
PT798295E (pt) | 1994-12-02 | 2003-07-31 | Yamanouchi Pharma Co Ltd | Novo derivado de amidinonaftilo ou sal deste |
US6017887A (en) | 1995-01-06 | 2000-01-25 | Sibia Neurosciences, Inc. | Peptide, peptide analog and amino acid analog protease inhibitors |
US5804560A (en) | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5691368A (en) | 1995-01-11 | 1997-11-25 | Hoechst Marion Roussel, Inc. | Substituted oxazolidine calpain and/or cathepsin B inhibitors |
DE19501841A1 (de) | 1995-01-23 | 1996-07-25 | Bayer Ag | Aminosäureamide |
DE19505932B4 (de) | 1995-02-21 | 2005-06-23 | Degussa Ag | Verfahren zur Herstellung von Oxazolidinonen, neue Oxazolidinone sowie Verwendung von Oxazolidinonen |
US5710129A (en) | 1995-02-23 | 1998-01-20 | Ariad Pharmaceuticals, Inc. | Inhibitors of SH2-mediated processes |
JPH08248579A (ja) | 1995-03-14 | 1996-09-27 | Mitsubishi Paper Mills Ltd | ハロゲン化銀写真感光材料及びその処理方法 |
US5776718A (en) * | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
EP0817778A1 (en) | 1995-03-24 | 1998-01-14 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
IL117940A (en) | 1995-04-19 | 2003-06-24 | Kumiai Chemical Industry Co | Benzylsulfide derivatives, process for their production and insecticide compositions containing them |
GB9508195D0 (en) | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
JPH11505522A (ja) | 1995-04-21 | 1999-05-21 | ノバルティス・アクチエンゲゼルシャフト | エンドセリン阻害剤としてのn−アロイルアミノ酸アミド |
JPH08319291A (ja) | 1995-05-25 | 1996-12-03 | Meiji Seika Kaisha Ltd | 新規セフェム誘導体 |
US6107329A (en) | 1995-06-06 | 2000-08-22 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5827866A (en) | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
US5827860A (en) | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
WO1996040753A1 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis |
TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
US6069130A (en) | 1995-06-07 | 2000-05-30 | Cor Therapeutics, Inc. | Ketoheterocyclic inhibitors of factor Xa |
WO1997001275A1 (en) | 1995-06-29 | 1997-01-16 | Merck & Co., Inc. | Combinations of inhibitors of farnesyl-protein transferase |
AU6317996A (en) | 1995-07-07 | 1997-02-10 | Sagami Chemical Research Center | Peptide derivatives and angiotensin iv receptor agonist |
GB9518552D0 (en) | 1995-09-11 | 1995-11-08 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
AU7710596A (en) | 1995-11-29 | 1997-06-19 | Nihon Nohyaku Co., Ltd. | Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides |
TW474946B (en) | 1995-12-15 | 2002-02-01 | Basf Ag | Novel compounds, the preparation and use thereof |
US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
DE69624728T2 (de) | 1995-12-29 | 2003-07-10 | Boehringer Ingelheim Pharma | Phenyl thiazol derivate mit antiherpesvirus eigenschaften |
US6008372A (en) | 1996-01-16 | 1999-12-28 | Warner-Lambert Company | Substituted dinaphthylmethyl and diheteroarylmethylacetyl histidine inhibitors of protein farnesyltransferase |
WO1997027200A1 (en) | 1996-01-26 | 1997-07-31 | Smithkline Beecham Plc | Thienoxazinone derivatives useful as antiviral agents |
US6288037B1 (en) | 1996-01-29 | 2001-09-11 | Basf Aktiengesellschaft | Substrates and inhibitors for cysteine protease ICH-1 |
WO1997031016A2 (en) | 1996-02-23 | 1997-08-28 | Ariad Pharmaceuticals, Inc. | New inhibitors of sh2-mediated processes |
DE19609955A1 (de) | 1996-03-14 | 1997-09-18 | Basf Ag | Amidonitrile, Verfahren zu ihrer Herstellung, ihre Verwendung als Kaltbleichaktivatoren oder optische Aufheller in Wasch-, Reinigungs- und Bleichmitteln sowie ihre Verwendung als Ausgangsmaterial bei der Herstellung von Amidocarbonsäuren und Amidocarbonsäure-Derivaten |
CA2204082A1 (en) | 1996-05-03 | 1997-11-03 | Michael William John Urquhart | Pharmaceutical compounds |
DE19621522A1 (de) | 1996-05-29 | 1997-12-04 | Hoechst Schering Agrevo Gmbh | Neue N-Acylsulfonamide, neue Mischungen aus Herbiziden und Antidots und deren Verwendung |
DE19621483A1 (de) | 1996-05-29 | 1997-12-04 | Hoechst Ag | Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE59706319D1 (de) | 1996-05-31 | 2002-03-21 | Basf Ag | Carbamoylcarbonsäureamidoxime |
DE19629717C1 (de) | 1996-07-25 | 1998-02-12 | Hoechst Ag | Verfahren zur katalytischen Herstellung von N-Acylglycinderivaten |
US5939527A (en) | 1996-07-30 | 1999-08-17 | Basf Aktiengesellschaft | Tetrapeptides as antitumor agents |
WO1998014450A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
JP4080541B2 (ja) | 1996-10-18 | 2008-04-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
EP0844248B1 (de) | 1996-10-28 | 2002-07-10 | Rolic AG | Vernetzbare, photoaktive Silanderivate |
JP2001503762A (ja) | 1996-11-12 | 2001-03-21 | ノバルティス アクチェンゲゼルシャフト | 除草剤として有用なピラゾール誘導体 |
IL129504A0 (en) | 1996-11-22 | 2000-02-29 | Elan Pharm Inc | N-(aryl/heteroaryl/alkylacetyl) amino acid amides pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
PL189827B1 (pl) | 1996-12-19 | 2005-09-30 | Isagro Spa | Kompozycje grzybobójcze |
DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
WO1998028269A1 (en) | 1996-12-23 | 1998-07-02 | Du Pont Pharmaceuticals Company | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS |
AR011164A1 (es) | 1997-02-28 | 2000-08-02 | Lilly Co Eli | Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o su sintesismediante el uso de dichos compuestos |
FR2762315B1 (fr) | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha |
WO1998052941A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
WO1998052558A1 (en) | 1997-05-23 | 1998-11-26 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
ATE399007T1 (de) | 1997-05-23 | 2008-07-15 | Bayer Pharmaceuticals Corp | Raf kinase hemmer |
ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
KR20010013977A (ko) | 1997-06-19 | 2001-02-26 | 블레어 큐. 퍼거슨 | 중성 p1 특이성 기를 갖는 인자 xa의 억제제 |
EP0897908A1 (de) | 1997-08-19 | 1999-02-24 | Roche Diagnostics GmbH | 3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente |
JP3002872B2 (ja) | 1997-09-05 | 2000-01-24 | ヒエン電工株式会社 | ケ−ブル吊り下げ用螺旋状支持具の引き紐通し具 |
JPH11100373A (ja) | 1997-09-26 | 1999-04-13 | Eisai Co Ltd | 新規フェノチアジン誘導体及びその医薬 |
US5872122A (en) | 1997-10-16 | 1999-02-16 | Monsanto Company | Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation |
PT1027328E (pt) | 1997-10-31 | 2006-11-30 | Aventis Pharma Ltd | Anilidas substituídas |
TR200001189T2 (tr) | 1997-11-05 | 2000-09-21 | Novartis Ag. | Dipeptid nitriller. |
KR100622138B1 (ko) | 1997-12-22 | 2006-09-13 | 바이엘 코포레이션 | 아릴 및 헤테로아릴 치환 헤테로고리형 우레아를 사용한라프 키나제의 저해 |
CZ299156B6 (cs) | 1997-12-22 | 2008-05-07 | Bayer Corporation | Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití |
KR20010052307A (ko) | 1998-05-05 | 2001-06-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 인터루킨-1β 전환 효소의 숙신아미드 저해제 |
CA2360740A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
DK1178958T3 (da) | 1999-03-15 | 2004-06-21 | Axys Pharm Inc | N-cyanomethylamider som proteaseinhibitorer |
WO2001012864A1 (fr) * | 1999-08-10 | 2001-02-22 | Nkk Corporation | Procede de production de feuillards d'acier lamines a froid |
US6420364B1 (en) * | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
CA2385130C (en) * | 1999-09-13 | 2009-10-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
EP2166122A1 (en) * | 1999-09-16 | 2010-03-24 | JFE Steel Corporation | Method of manufacturing high strength steel |
KR100419080B1 (ko) * | 1999-09-28 | 2004-02-18 | 제이에프이 엔지니어링 가부시키가이샤 | 고장력 열연강판 및 그 제조방법 |
EP1149925B1 (en) * | 1999-09-29 | 2010-12-01 | JFE Steel Corporation | Sheet steel and method for producing sheet steel |
KR100401272B1 (ko) * | 1999-09-29 | 2003-10-17 | 닛폰 고칸 가부시키가이샤 | 박강판 및 박강판의 제조방법 |
CN1331183A (zh) | 2000-06-28 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人dna修复蛋白10.23和编码这种多肽的多核苷酸 |
-
2000
- 2000-09-08 US US09/655,351 patent/US6420364B1/en not_active Expired - Lifetime
-
2001
- 2001-03-14 MX MXPA03001947A patent/MXPA03001947A/es active IP Right Grant
- 2001-03-14 CZ CZ2003603A patent/CZ2003603A3/cs unknown
- 2001-03-14 CN CNB018153143A patent/CN1303067C/zh not_active Expired - Fee Related
- 2001-03-14 US US09/808,439 patent/US6525052B2/en not_active Expired - Lifetime
- 2001-03-14 BR BR0113740-9A patent/BR0113740A/pt not_active Withdrawn
- 2001-03-14 CA CA002417177A patent/CA2417177A1/en not_active Abandoned
- 2001-03-14 YU YU17003A patent/YU17003A/sh unknown
- 2001-03-14 WO PCT/US2001/008084 patent/WO2002020485A1/en not_active Application Discontinuation
- 2001-03-14 UA UA2003042888A patent/UA73378C2/uk unknown
- 2001-03-14 HU HU0303934A patent/HUP0303934A2/hu unknown
- 2001-03-14 IL IL15408001A patent/IL154080A0/xx unknown
- 2001-03-14 PL PL01361038A patent/PL361038A1/xx not_active Application Discontinuation
- 2001-03-14 JP JP2002525107A patent/JP2004508356A/ja active Pending
- 2001-03-14 SK SK286-2003A patent/SK2862003A3/sk not_active Application Discontinuation
- 2001-03-14 AU AU2001245694A patent/AU2001245694A1/en not_active Abandoned
- 2001-03-14 KR KR10-2003-7003417A patent/KR20030051644A/ko not_active Application Discontinuation
- 2001-03-14 EP EP01918641A patent/EP1322613A1/en not_active Withdrawn
- 2001-03-14 EA EA200300348A patent/EA005203B1/ru not_active IP Right Cessation
- 2001-03-14 NZ NZ525169A patent/NZ525169A/en unknown
- 2001-03-14 EE EEP200300093A patent/EE200300093A/xx unknown
- 2001-11-02 US US10/001,134 patent/US6756372B2/en not_active Expired - Lifetime
-
2002
- 2002-10-01 US US10/261,994 patent/US6787540B2/en not_active Expired - Lifetime
- 2002-10-01 US US10/261,993 patent/US6720319B2/en not_active Expired - Lifetime
-
2003
- 2003-02-06 ZA ZA200301032A patent/ZA200301032B/xx unknown
- 2003-02-24 BG BG107585A patent/BG107585A/bg active Pending
- 2003-03-06 HR HR20030163A patent/HRP20030163A2/hr not_active Application Discontinuation
- 2003-03-07 NO NO20031065A patent/NO20031065D0/no not_active Application Discontinuation
- 2003-04-24 US US10/422,471 patent/US7056915B2/en not_active Expired - Lifetime
- 2003-04-24 US US10/422,473 patent/US6982272B2/en not_active Expired - Lifetime
- 2003-05-29 US US10/448,698 patent/US6858623B2/en not_active Expired - Lifetime
-
2004
- 2004-05-20 HK HK04103580A patent/HK1060565A1/xx not_active IP Right Cessation
- 2004-09-09 US US10/937,533 patent/US7265132B2/en not_active Expired - Lifetime
- 2004-09-09 US US10/937,636 patent/US7279472B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20030163A2 (en) | Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases | |
AU782246B2 (en) | Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
OBST | Application withdrawn |